

## CURRICULUM VITAE

**Steven M. Smith, PharmD, MPH, FCCP, FAHA**

---

### **GENERAL INFORMATION**

Address: Department of Pharmaceutical Outcomes & Policy  
University of Florida  
P.O. Box 100496  
Gainesville, Florida 32610-0496

Office: 352-273-5134  
Fax: 352-273-6270  
Email: [ssmith@cop.ufl.edu](mailto:ssmith@cop.ufl.edu)  
Websites: <https://cvmedlab.org/>  
<https://www.stevenmsmith.org/>  
<https://pharmacy.ufl.edu/profile/smith-steven-1/>

Present Position: Associate Professor & Chair  
Department of Pharmaceutical Outcomes & Policy  
College of Pharmacy

Co-Director, Center for Integrative Cardiovascular and Metabolic Disease

University of Florida

### **EDUCATION**

2016–2019	University of Florida	Graduate Certificate in Biomedical Informatics
2008–2011	University of Florida	Master of Public Health (concentration: biostatistics)
2003–2007	University of Florida	Doctor of Pharmacy
2002–2003	Santa Fe College	Associate of Arts

### **POSTGRADUATE TRAINING**

*Clinical Faculty Scholars Program*, Colorado Clinical and Translational Sciences Institute (CCTSI), University of Colorado, Aurora, CO; Program Mentors: Anne Libby, PhD and Allen Prochazka, MD, MSc; 2013-2014

*Advanced Postgraduate Program in Clinical Investigation (APPCI) Fellowship*, University of Florida, Gainesville, FL; Directors: Marian C. Limacher, MD, FACC, and Nabih Asal, PhD, FACE; Clinical Research Curriculum Award K30RR022258 from the National Center for Research Resources, 2009-2011

*Postdoctoral Fellowship in Family Medicine Clinical Research*, Departments of Pharmacotherapy & Translational Research and Community Health & Family Medicine, Colleges of Pharmacy and Medicine, University of Florida, Gainesville, FL; Director: John G. Gums, PharmD, FCCP, 2008-2011

*Hospital Practice Residency*, North Florida/South Georgia Veterans Health System, Gainesville, FL;  
Director: Mark Burlingame, PharmD, BCPS, 2007-2008

## **PROFESSIONAL CREDENTIALS**

Licensure: Florida: PS43084 (2007 – present; active)  
Colorado: PHA-19305 (2011 – present; inactive)

Certifications: Board-Certified Pharmacotherapy Specialist (BCPS), #312178, 2012 – 2019  
American Society of Hypertension Certified Hypertension Clinician (CHC), 2016 – 2026

## **ACADEMIC APPOINTMENTS**

2024 – present	<i>Associate Professor</i> (with tenure), Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, FL
2024 – present	<i>Associate Professor</i> (courtesy appointment), Division of Cardiovascular Medicine, Department of Medicine, College of Medicine, University of Florida, Gainesville, FL
2022 – 2024	<i>Assistant Professor</i> (tenure-track), Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, FL
2022 – 2024	<i>Assistant Professor</i> (courtesy appointment), Division of Cardiovascular Medicine, Department of Medicine, College of Medicine, University of Florida, Gainesville, FL
2016 – 2022	<i>Assistant Professor</i> (tenure-track), Department of Pharmacotherapy & Translational Research, College of Pharmacy, University of Florida, Gainesville, FL
2016 – 2018	<i>Assistant Professor</i> (joint appointment), Department of Community Health & Family Medicine, College of Medicine, University of Florida, Gainesville, FL
2014 – 2016	<i>Clinical Assistant Professor</i> (joint appointment), Department of Community Health & Family Medicine, College of Medicine, University of Florida, Gainesville, FL
2014 – 2016	<i>Clinical Assistant Professor</i> , Department of Pharmacotherapy & Translational Research, College of Pharmacy, University of Florida, Gainesville, FL
2011 – 2014	<i>Assistant Professor</i> , Department of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Denver, CO
2008 – 2011	<i>Postdoctoral Fellow &amp; Clinical Instructor</i> , Departments of Pharmacotherapy & Translational Research and Community Health & Family Medicine, Colleges of Pharmacy and Medicine, University of Florida
2008 – 2011	<i>Clinical Instructor</i> (adjunct), Physician's Assistant Program, College of Medicine, University of Florida

## **LEADERSHIP & ADMINISTRATIVE EXPERIENCE**

- 2024 – present     *Chair*, Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, FL
- 2023 – 2024     *Interim Chair*, Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, FL
- 2023 – present     *Director*, UF Center for Integrative Cardiovascular and Metabolic Disease
- 2018 – 2023     *Associate Director (Population Sciences)*, UF Center for Integrative Cardiovascular and Metabolic Disease
- 2018 – present     *Program Coordinator*, UF PharmD/MPH Joint Degree Program

## **PROFESSIONAL PRACTICE EXPERIENCE**

- 2014 – 2016     *Clinical Pharmacist*, Community Health & Family Medicine, University of Florida, Gainesville, FL
- 2012 – 2014     *Director*, Pharmacist-Physician Collaborative Hypertension Clinic, University Medicine Lowry, University of Colorado Hospital, Aurora, CO
- 2011 – 2014     *Clinical Pharmacist*, University Medicine Lowry, University of Colorado Hospital, Aurora, CO
- 2008 – 2011     *Postdoctoral Fellow*, Departments of Pharmacotherapy & Translational Research and Community Health & Family Medicine, University of Florida, Gainesville, FL
- 2009 – 2011     *Florida Medicaid Beneficiary Auditor*, Agency for Health Care Administration (AHCA), State of Florida, Tallahassee, FL
- 2008 – 2011     *Research Pharmacist*, North Florida/South Georgia Veterans Health System, Gainesville, FL
- 2008 – 2010     *Health Information Provider*, Disease Prevention and Health Promotion Program, Suwannee River Area Health Education Center (SRAHEC), Alachua, FL
- 2007 – 2008     *Staff Pharmacist* (part time, intermittent), North Florida/South Georgia Veterans Health System, Gainesville, FL
- 2007 – 2008     *Pharmacy Resident*, North Florida/South Georgia Veterans Health System, Gainesville, FL

## **HONORS & AWARDS**

- 2023     *Fellow*, American Heart Association, Council on Hypertension
- 2021     *Teaching and Service Excellence Award*, University of Florida College of Pharmacy
- 2019     *Provost Excellence Award for Assistant Professors*, University of Florida
- 2018     *Fellow*, American College of Clinical Pharmacy

- 2017                      *Teaching and Service Excellence Award*, University of Florida College of Pharmacy
- 2017                      *Delta Omega (Public Health Honor Society)*, University of Florida College of Public Health and Health Professions, Beta Upsilon Chapter
- 2015                      *2015 New Investigator Award*, American College of Clinical Pharmacy (this award recognizes the ACCP member <6 years since completion of training whose research program is especially noteworthy in theme and productivity)
- 2014 – 2016            *Institute of Medicine (now National Academy of Medicine) Anniversary Fellow in Pharmacy*, Institute of Medicine, The National Academies of Science, Washington, D.C. (this 2-year IOM fellowship is awarded to only one pharmacist nationwide)
- 2014                      *The "Great Eight" Best Papers* finalist and second runner-up, American College of Clinical Pharmacy 2014 Annual Meeting

## **GRANT & RESEARCH ACTIVITY**

### **Current Funding**

Sponsor: NIH/NHLBI (2R01 HL132448)  
Title: "Antihypertensive Mechanisms of Minocycline in Resistant Hypertension"  
Time Period: December 1 2023 – January 31 2028  
Total Costs: \$3,679,089 (Total Direct: \$2,691,443)  
Role: MPI/Contact PI

Sponsor: NIH/NHLBI (R03 HL172123)  
Title: "Hypertension Prediction and Identification in All of Us"  
Time Period: September 10 2023 – August 31 2025  
Total Costs: \$305,000 (Total Direct: \$200,000)  
Role: Co-I (PI: McDonough, UF)

Sponsor: NIH/NHLBI (R21 HL159576)  
Title: "High-throughput screening for antihypertensive prescribing cascades"  
Time Period: August 1 2022 – July 31 2025  
Total Costs: \$228,750 (Total Direct: \$150,000)  
Role: PI

Sponsor: Department of Defense  
Title: "Women's Ischemia Trial to Reduce Events in Non-Obstructive CAD (WARRIOR)"  
Time Period: 9/15/2017-9/14/2024  
Total Costs: \$14,915,728 (Total Direct: \$10,426,809)  
Role: Co-I

Sponsor: UF CTSI (Precision Public Health Pilot Program)  
Title: "ReCLaiMeD: Using community healthcare workers to improve blood pressure control among food insecure hypertensive adults"  
Time Period: 05/01/2023 – 10/30/2024  
Total Costs: \$50,000  
Role: Co-I (PI: Staras, UF)

## Pending Applications

Sponsor: MacArthur Foundation, 100&Change  
Title: PRISM (Population Research, Innovation, and Systems for health equity)  
Time Period: January 1 2025 – December 31 2030  
Total Costs: \$100,000,000 / UF Subaward: \$20,000,000  
Role: MPI/Data Coordinating Center PI

Sponsor: NIH/NHLBI (R01 HL171387)  
Title: "Analyzing effectiveness of ongoing natural experiments in telehealth and self-monitoring strategies for BP control in diverse health systems and patients"  
Time Period: Sep 1 2024 – Aug 31 2029  
Total Costs: \$3,812,207 (Total Direct: \$3,246,353)  
Role: MPI/Contact PI  
**\*\*Pending NHLBI Advisory Council Review (Scored at 6<sup>th</sup> percentile; NHLBI payline ≤14<sup>th</sup> percentile)**

Sponsor: NIH/NHLBI (R01 HL177109)  
Title: "CVH Track: Innovations in CVD Risk Prediction for Young Adults"  
Time Period: Sept 1 2024 – July 31 2029  
Total Costs: \$9,505,789 (Total Direct: \$7,472,720); UF Subaward: \$2,486,378 total (\$1,677,988 direct)  
Role: MPI / Data Core PI

## Completed Grants (reverse chronological order)

Sponsor: American Heart Association Predoctoral Fellowship Award (for Earl Morris, PharmD, MPH)  
Title: Real-World Trajectories of Xanthine Oxidase Inhibitor Use and Downstream Cardiovascular Outcomes  
Time Period: 01/01/2023 – 12/31/2023  
Amount: \$32,553  
Role: Primary Mentor

Sponsor: NIH/NHLBI (K01 HL138172)  
Title: "Advancing Personalized Hypertension Care through Big Data Science"  
Time Period: 07/15/2018-06/30/2023  
Total Costs: \$725,793 (Total Direct: \$760,778)  
Role: PI

Sponsor: UF COP (PROSPER Award)  
Title: "The External Exposome and Access to Novel Therapies for Improving Cardiorenal Outcomes among Medicare Beneficiaries with Type 2 Diabetes"  
Time Period: June 2021 – June 2022  
Total Direct Costs: \$30,000  
Role: Co-I (PI: Guo J)

Sponsor: UF CTSI  
Title: "Social Determinants of Health and Real-World Adoption of Novel Therapies for Reducing Cardiorenal Risk in Patients with Type 2 Diabetes"  
Time Period: June 2021 – June 2022  
Total Direct Costs: \$20,000  
Role: Co-I (PI: Guo J)

Sponsor: Patient-Centered Outcomes Research Institute (PaCR Grant Administrative Supplement)  
Title: "Using PCORnet to Compare Blood Pressure Control Strategies"

Total Direct Costs (UF): \$95,956  
Role: Co-Investigator (PI: M. Pletcher [UCSF])

Sponsor: UF COP (PROSPER Award)  
Title: "Operationalizing High-Throughput Screening Prescription Sequence Symmetry Analysis to Discover New Prescribing Cascades"  
Time Period: January 2021 – December 2021  
Total Direct Costs: \$29,867  
Role: Co-PI

Sponsor: NIH/NHLBI (R18 HL116259)  
Title: "MEDication Focused Outpatient Care for Underutilization of Secondary Prevention (MED-FOCUS)"  
Time Period: 4/1/2014 – 3/31/2019  
Role: Site Investigator

Sponsor: PROSPER Grant (Faculty Development), College of Pharmacy, University of Florida  
Title: "Faculty Development: Developing Expertise in Pharmacoepidemiology"  
Time Period: 04/26/2017 – 04/25/2018  
Total Direct: \$ 5,094.14  
Role: Principal Investigator

Sponsor: Pilot Grants program, Clinical & Translational Science Institute, University of Florida  
Title: "Hypertension prevalence and disparities in the OneFlorida Data Trust"  
Time Period: 10/10/2016 – 4/09/2018  
Total Direct: \$13,835  
Role: Principal Investigator

Sponsor: National Academy of Medicine  
Unrestricted Research Grant for NAM Fellowship  
Time Period: 10/20/2014 – 10/20/2017  
Total Direct: \$25,000  
Role: Principal Investigator

Sponsor: PROSPER Grant (Research Enhancement), College of Pharmacy, University of Florida  
Title: "Enhancing Research Data Access and Availability to University of Florida College of Pharmacy Faculty"  
Time Period: 8/1/2016 – 7/30/2017  
Total Direct: \$40,000  
Role: Co-Investigator

Sponsor: NIH/NHGRI (U01 HG007269)  
Title: "Genomic Medicine Implementation: The Personalized Medicine Program (PMP): Genotyping in Family Medicine Clinics"  
Time Period: 1/1/2015 – 06/30/2016  
Role: Site Co-Investigator

Sponsor: UF Women's Health / Sex & Gender Differences in Health Open Access Publishing Fund  
Title: "Cardiovascular and Mortality Risk of Apparent Resistant Hypertension in Women With Suspected Myocardial Ischemia: A Report From the NHLBI-Sponsored WISE Study"  
Time Period: 08/2014  
Total Direct: \$1,500  
Role: Principal Investigator

Sponsor: ALSAM Foundation

Title: "Patient-Perceived Treatment Burden and Medication Non-adherence"

Time Period: 7/1/2013 – 2/7/2014

Total Direct: \$150,000

Role: Principal Investigator

Sponsor: Colorado Health Foundation

Title: "Pharmacist Managed Medicare Outreach in Primary Care: Lowering Costs and Improving Health Outcomes"

Time Period: 10/1/2012 – 2/7/2014

Total Direct: \$166,020

Role: Co-Principal Investigator (PI: K Trinkley)

Sponsor: University of Colorado Hospital / University of Colorado School of Medicine

Title: "Physician-Pharmacist Collaborative Hypertension Clinic"

Time Period: 9/1/2012 – 10/31/2013

Total Direct: \$25,000

Role: Principal Investigator

Sponsor: Colorado Health Foundation

Title: "An academic model for providing adult primary care pharmacy consult services"

Time Period: 9/1/2011 – 8/30/2012

Total Direct: \$209,724

Role: Co-investigator (PI: G Moore)

Sponsor: NIH, National Heart Lung and Blood Institute, R01 HL091841

Title: "A Collaborative Model to Improve BP Control and Minimize Racial Disparities NOW (CAPTION)"

Time Period: 11/1/2008 – 6/30/2011

Amount: \$6,738,456 (direct); \$9,296,523 (total); \$47,900 (total to site)

Role: Site Principal Investigator (Trial PI: B Carter)

Sponsor: Sanofi-aventis

Title: "Venous Thromboembolism Project (VTEProject)"

Time Period: 1/1/2010 – 6/30/2011

Amount: \$404,300 (direct); \$509,418 (total)

Role: Co-Principal Investigator (PI: J Gums)

Sponsor: Ortho-McNeil Janssen Pharmaceuticals, Inc.

Title: "Infectious Disease Outcomes Project (iDOP)"

Time Period: 5/1/2009 – 6/30/2011

Amount: \$295,000 (direct); \$371,700 (total)

Role: Co-Investigator (PI: J Gums)

Sponsor: Agency for Healthcare Research and Quality

Title: "Establishing Benchmarks for the Medical Office Survey on Patient Safety (SOPS)"

Time Period: 4/1/2009 – 5/30/2009

Amount: \$200 (total to site)

Role: Site Principal Investigator (PI: G Kuo)

Sponsor: Wyeth Pharmaceuticals

Title: "Postdoctoral Research Project: Antimicrobial Resistance Management"

Time Period: 1/1/2009 – 6/30/2011

Amount \$13,500 (direct)

Role: Principal Investigator



## Unfunded Proposals

Sponsor: PCORI

Title: "BP Tech: A Comparative Effectiveness and Implementation Study of Next Generation Technology for Blood Pressure Management in Disadvantaged Patients"

Time Period: July 1 2024 – June 30 2029

Total Costs: \$14,960,312 (UF Subaward Total: \$1,279,728; Total Direct: \$914,092)

Role: Co-Investigator (UF Subaward PI)

Sponsor: PhRMA Foundation Predoctoral Fellowship Award (for Shailina Keshwani, MS)

Title: Analgesic Use Among Medicare Beneficiaries

Time Period: July 1, 2024 – June 30, 2025

Amount: \$30,000

Role: Primary Mentor

Sponsor: PCORI

Title: "BP Tech: A Comparative Effectiveness-Implementation Study of Next Generation BP Control Technology"

Time Period: Jan 1 2024 – Dec 31 2029

Total Costs: \$13,056,011 (UF Subaward: \$1,246,867 total, \$890,619 direct)

Role: Co-Investigator/Site PI (Overall PI: M. Pletcher, UCSF)

Sponsor: NIH/NCATS (U01)

Title: "Eureka on FHIR: Advancing blood pressure control research through efficient multisite linkage of EHR-, patient- and device-generated data"

Time Period: July 1 2022 – June 30 2025

Total Costs: \$4,850,505

Role: Co-I (MPIs: Pletcher/Fontil/Beatty)

Sponsor: NIH/NCATS (U01)

Title: "Eureka on FHIR: Advancing blood pressure control research through efficient multisite linkage of EHR-, patient- and device-generated data"

Time Period: Jan 1 2022 – Dec 31 2025

Total Costs: \$4,839,123

Role: Co-I (MPIs: Pletcher/Fontil/Beatty)

Sponsor: NIH/NHLBI (OTA – COVID-19-Related Other Agreement)

Title: "Leveraging the OneFlorida Research Consortium for Large-Scale COVID-19 Observational Studies"

Role: Principal Investigator

Sponsor: University of Florida

Title: "UF Moonshot Program 2019: Cardiometabolic Research"

Amount: \$750,000 (total)

Role: Co-Principal Investigator

Sponsor: UF CTSI KL2 (KL2 Scholars Program)

Title: "Combining Biomedical Informatics and Pharmacoepidemiology to Improve Antihypertensive Drug Selection using Real World EHR Data"

Amount: \$150,000

Role: Principal Investigator



Sponsor: ASHP Foundation

Title: "Innovating Hypertension Management in the Primary Care Setting using Pharmacist-Physician Collaborative Care with Home Monitoring and Self-Management"

Amount: \$81,000 (total)

Role: Principal Investigator

Sponsor: UF CTSI KL2 Program

Title: "Blood Pressure Treatment: Assessing Risks under current population Goals to Enhance Therapy (BP-TARGET)"

Amount: \$150,000 (total)

Role: Principal Investigator

Sponsor: NIH/NIMHD

Title: "Optimizing Precision of HTN Care to Maximize BP Control (OPTI-BP)"

Amount: \$1,852,475 (total)

Role: Co-Investigator

Sponsor: Higi, LLC.

Title: "Out-of-Office Blood Pressure: Comparing Measurements by a Public Kiosk System and Standard Out-of-Office Techniques and Ascertaining Patient and Physician Preferences"

Amount: \$33,462 (total direct)

Role: Principal Investigator

Sponsor: American College of Clinical Pharmacy Research Institute (Futures Mentored Award)

Title: "Improving Blood Pressure Control in a Diverse Patient Population through Home Monitoring and Self-Management Under Physician-Pharmacist Collaborative Care."

Amount \$47,662 (total direct)

Role: Principal Investigator

Sponsor: American Heart Association (Strategically-Focused Research Network in Hypertension)

Title: "Concurrent Hypertension Control in Older Women (NO-HOW)"

Time Period: 4/1/2015 – 3/31/2019

Amount: \$933,145 (total direct)

Role: Co-Investigator (PIs: Pepine CJ and Cooper-DeHoff RM)

Sponsor: PROSPER Grant, College of Pharmacy, University of Florida

Title: "Out-of-Office Blood Pressure: Comparing Measurements by a Public Kiosk System and Standard Out-of-Office Techniques and Ascertaining Patient and Physician Preferences"

Time Period: 4/1/2015 – 3/30/2016

Amount: \$33,462 (total direct)

Role: Principal Investigator

Sponsor: PhRMA Foundation

Title: "Objective and Subjective Measures of Medication Regimen Complexity and Their Impact on Medication Adherence and Outcomes in Hypertensive Patients"

Time Period: 02/01/2013-1/31/2013

Amount: \$50,000 (total direct)

Role: Principal Investigator

Sponsor: NIH/NHLBI

Title: "Enhancing Guideline Concordance for Modifiable CVD Risk Factors in Primary Care"

Time Period: 12/01/2013-11/30/2018

Amount: \$2,384,361 (total direct)

Role: Co-Investigator (PI: Hammermeister K)

**PUBLICATIONS** (reverse chronological order; underline denotes my student or postdoc; † denotes senior/corresponding author [if different from first author]; the most up-to-date list of indexed articles can be accessed [here](#).)

### **Original Research**

#### Published/In Press:

1. Alshahawey M, Jafari E, **Smith SM**, McDonough CW. Characterizing apparent treatment-resistant hypertension in the United States: Insights from the All of Us Research Program. *J Am Med Inform Assoc* 2024; [in press].
2. Chen WH, Li Y, Chen A, Allen JM, Guo Y, Billello L, **Smith SM**, Yang L, Goodin AJ, Bian J, Guo J. Social Determinants of Health and Newer Glucose-lowering Drugs Adoption among US Medicare Beneficiaries with Type 2 Diabetes. *J Managed Care Pharm* 2024; [in press].
3. Riaz M, Guo J, **Smith SM**, Dietrich EA, Winchester DE, Park H. Comparative Genitourinary Safety of Sodium-Glucose Cotransporter-2 Inhibitors among Patients with Heart Failure with Preserved Ejection Fraction: A Cohort Study. *Am J Cardiovasc Drugs* 2024;24(3):455-464.
4. Mehanna M, McDonough C, **Smith SM**, Gong Y, Gums JG, Chapman A, Johnson JA, Cooper-DeHoff RM. Integrated Metabolomics Analysis Reveals Mechanistic Insights into Variability in Blood Pressure Response to Thiazide Diuretics and Beta Blockers. *Clin Transl Science* 2024;17(5):e13816.
5. Desai R, Unigwe I, Riaz M, **Smith SM**, Shukla AM, Mohandas R, Jeon N, Park H. Comparative Safety of Long-Acting Versus Short-Acting Erythropoiesis-Stimulating Agents Among Patients Undergoing Hemodialysis. *Clin Pharmacol Ther* 2024;116(1):217-224.
6. Huang W, Ahmed M, Morris EJ, Yang L, O'Neal L, Hernandez I, Bian J, Kimmel S, **Smith SM**, Guo J. Trajectories of sacubitril/valsartan adherence among Medicare beneficiaries with heart failure. *JACC Advances* 2024; doi: 10.1016/j.jacadv.2024.100958 [epub ahead of print].
7. Riaz M, **Smith SM**, Dietrich EA, Winchester DE, Guo J, Park H. Comparative effectiveness of sacubitril/valsartan versus angiotensin receptor blockers in patients with heart failure with preserved ejection fraction: A cohort study. *Am J Health Syst Pharm* 2024; doi: 10.1093/ajhp/zxae053 [epub ahead of print]
8. Desai R, **Smith SM**, Brown J, Mohandas R, Park H. Risk of fractures with concomitant use of Calcium Channel Blockers and Selective Serotonin Reuptake Inhibitors. *Ann Pharmacother* 2024; doi: 10.1177/1060028023121828 [Epub ahead of print].
9. Chen WH, Li Y, Yang L, Allen JM, Shao H, Donahoo WT, Billello L, Hu X, Shenkman EA, Bian J, **Smith SM**, Guo J. Geographic Variation and Racial Disparities in Adoption of Newer Glucose-lowering Drugs with Cardiovascular Benefits among US Medicare Beneficiaries with Type 2 Diabetes. *PLOS One* 2024;19(1):e0297208.
10. Smith KM, Keshwani S, Walsh MG, Winterstein AG, Gurka MJ, Libby A, Hogan W, Pepine CJ, Cooper-DeHoff RM, **Smith SM**†. Initial antihypertensive prescribing in relation to blood pressure among Florida Medicaid and Medicare recipients in the OneFlorida+ Research Consortium. *Hypertension* 2024;81(2):e7-e9.

11. Wang HM, Morris EJ, Vouri SM, Keshwani S, Schmidt S, Pepine CJ, **Smith SM**†. Modifiable statin characteristics associated with potential statin-related prescribing cascades. *Pharmacotherapy* 2023;43(12):1307-16.
12. Li J, Richards EM, Handberg EM, **Smith SM**, Pepine CJ, Alakarad E, Forsmark CE, Raizada MK. Reprogramming of transcriptional profile of colonic organoids from patients with high blood pressure by minocycline. *Am Heart J Plus: Cardiology Research and Practice* 2023;36:100343.
13. Keshwani S, Brown J, **Smith SM**, Lo-Ciganic WH, Yang S, Smolinski NE, Hincapie-Castillo JM. Trends in prescribing of non-steroidal anti-inflammatory medications in the US ambulatory care setting during the evolving drug overdose crisis, 2006-2016. *J Pain* 2023;24(11):1994-2002.
14. Riaz M, **Smith SM**, Dietrich EA, Winchester DE, Guo J, Park H. Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors among patients with heart failure with preserved ejection fraction. *Pharmacotherapy* 2023;43(10):1024-1031.
15. Penn MS, MacRae C, Goldfaden RF, Choksi RR, **Smith SM**, Wrenn D, Saghir MX, Klemes AB. Association of Chronic Neutrophil Activation with Risk of Mortality. *PLoS One* 2023;18(7):e0288712.
16. Vouri SM, Morris EJ, Walsh M, Agalliu J, Dempsey A, Hochleitner L, Muschett MR, Schmidt S, Pepine CJ, **Smith SM**†. High-throughput screening for prescribing cascades among real world initiators of statins. *Pharmacoepidemiol Drug Saf* 2023;32(7):773-82.
17. Riaz M, **Smith SM**, Dietrich EA, Winchester D, Guo J, Park H. Trends in pharmacotherapy utilization among patients with heart failure with preserved ejection fraction. *Am Heart J Plus: Cardiology Research and Practice* 2023;26:100259.
18. Chamberlain AM, Cooper-DeHoff RM, Fontil V, Nilles EK, Shaw KM, Smith M, Lin F, Vittinghoff E, Maeztu C, Todd J, Carton T, O'Brien EC, Faulkner M, Wozniak G, Rakotz M, Sanchez E, **Smith SM**, Polonsky TS, Ahmad FS, Liu M, McClay JC, VanWormer JJ, Taylor BW, Chrischilles EA, Wu S, Viera AJ, Ford DE, Hwang W, Knowlton KU, Pletcher MJ. Disruption in blood pressure control with the COVID-19 pandemic: A study of 24 US health systems in the PCORnet Blood Pressure Control Laboratory. *Mayo Clin Proc* 2023;98(5):662-75.
19. Wang GHM, Morris E, **Smith SM**, Hallas J, Vouri SM. Continued potassium supplementation use following loop diuretic discontinuation in older adults: An evaluation of a prescribing cascade relic. *J Am Geriatr Soc* 2023;71(2):505-515.
20. Allen JM, Surajbali D, Nguyen QD, Kuczek J, Tran M, Hachey B, Field C, Shoulders BR, **Smith SM**, Voils SA. Impact of piperacillin-tazobactam dosing in septic shock patients using real-world evidence: An observational, retrospective cohort study. *Ann Pharmacother* 2023;57(6):653-661.
21. **Smith SM**, Winterstein AG, Gurka MJ, Walsh MG, Keshwani S, Libby A, Hogan W, Pepine CJ, Cooper-DeHoff RM. Initial antihypertensive regimens in newly treated patients: Real world evidence from the OneFlorida Clinical Research Network. *J Am Heart Assoc* 2023;12:e026652.
22. Mehanna M, McDonough CW, **Smith SM**, Gong Y, Gums JG, Chapman AB, Johnson JA, Cooper-DeHoff RM. Influence of genetic West African ancestry on metabolomics among hypertensive patients. *Metabolites*, 2022;12(9):783.
23. Desai R, Park H, Brown J, Mohandas R, Pepine CJ, **Smith SM**†. Comparative safety and effectiveness of aldosterone antagonists versus beta-blockers as fourth line agents in patients with apparent resistant hypertension. *Hypertension* 2022;79(10):2305-15.

24. Hwang AY, Cardel M, **Smith SM**. Racial and Ethnic Differences in Blood Pressure Before and After the 2016 United States General Election. *Am J Hum Biol* 2022;34(10):e23785.
25. Park H, Desai R, Liu X, **Smith SM**, Hincapie-Castillo J, Henry L, Goodin A, Gopal S, Pepine C, Mohandas R. Medicare Bundled Payment Policy on Anemia Care, Major Adverse Cardiovascular Events, and Mortality Among Adults Undergoing Hemodialysis. *Clin J Am Soc Nephrol* 2022;17(6):851-860.
26. Desai R, Brown JD, Mohandas R, Park H, **Smith SM**<sup>†</sup>. Norepinephrine reuptake inhibitors and risk of antihypertensive treatment intensification and major adverse cardiovascular events in patients with stable hypertension. *Pharmacotherapy* 2022;42:472-82.
27. Desai R, Park H, Brown J, **Smith SM**. Risk of obstructive sleep apnea in adults with resistant hypertension. *Pharmacoepidemiology* 2022;1(1):26-32.
28. **Smith SM**, Desai R, Walsh MG, Nilles EK, Shaw K, Smith M, Chamberlain AM, Derington CG, Bress AP, Chuang CH, Ford DE, Taylor BW, Chandaka S, Patel LP, McClay J, Priest E, Fuloria J, Doshi K, Ahmad FS, Viera AJ, Faulkner M, O'Brien EC, Pletcher MJ, Cooper-DeHoff RM. Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and COVID-19 severity: A patient-level analysis of the PCORnet blood pressure control lab. *Am Heart J Plus* 2022;13:100112.
29. Vouri SM, Morris J, Jiang X, Hofer AK, Schmidt S, Pepine CJ, Winterstein AG, **Smith SM**. Evaluation of a beta-blocker – edema – loop diuretic prescribing cascade: A prescription sequence symmetry analysis. *Am J Hypertens* 2022;35(7):601-609.
30. Tang H, Kimmel SE, **Smith SM**, Cusi K, Shi W, Gurka M, Winterstein AG, Guo J. Comparable cardiorenal benefits of SGLT2 inhibitors and GLP-1RAs in Asian and White populations: An updated meta-analysis of results from randomized clinical trials. *Diabetes Care* 2022;45(4):1007–1012.
31. Tang H, Kimmel S, Hernandez I, Brooks M, Cusi K, **Smith SM**, Wei-Long S, Winterstein A, Magnani J, Guo J. Are novel glucose-lowering agents' cardiorenal benefits generalizable to individuals of black race? A meta trial sequential analysis to address disparities in cardiorenal outcome trial enrollment. *Diab Obes Metab* 2022;24(1):154-9.
32. Holmes HR, Li Q, Xu K, Kim S, Richards EM, Keeley EC, Handberg EM, **Smith SM**, Raizada MK, Pepine CJ, Cooper-DeHoff RM. Antihypertensive medication adherence trends by sex and drug class: A pilot study. *Am Heart J Plus*, 2021;5:100023.
33. Riaz M, Dietrich EA, **Smith SM**, Pepine CJ, Park H. Effectiveness of sacubitril/valsartan versus aldosterone antagonists in heart failure with reduced ejection fraction: A retrospective cohort study. *Pharmacotherapy* 2021;41:710-21.
34. Mehanna M, McDonough CW, **Smith SM**, Gong Y, Gums JG, Chapman AB, Johnson JA, McIntyre L, Cooper-DeHoff RM. Metabolomics signature of plasma renin activity and linkage with blood pressure response to beta blockers and thiazide diuretics in hypertensive European American patients. *Metabolites* 2021;11(9):645.
35. Pepine CJ, Handberg E, Sumners E, Dasa O, **Smith SM**, Cooper-DeHoff RM, Raizada MK. Potential of Minocycline for Treatment of Resistant Hypertension. *Am J Cardiol* 2021;156:147-9.
36. Dasa O, **Smith SM**, Howard G, Cooper-DeHoff RM, Gong Y, Handberg E, Pepine CJ. Association Between Short-term Visit-to-Visit Blood Pressure Variability and Long-term Mortality Among Patients with Coronary Artery Disease. *JAMA Network Open*, 2021;4(4):e218418.

37. Derington CG, Cohen JB, Mohanty AF, Greene TH, Cook J, Ying J, Wei G, Herrick JS, Stevens VW, Jones BE, Wang L, Zheutlin A, South AM, Hanff TC, **Smith SM**, Cooper-DeHoff RM, King JB, Alexander GC, Berlowitz DR, Ahmad FS, Penrod J, Hess R, Conroy MB, Fang J, Rubin MA, Beddhu S, Cheung AK, Xia W, Kazis L, Moran AE, Weintraub WS, Bress AP. Association between angiotensin-converting enzyme inhibitor or angiotensin-II receptor blocker use and COVID-19 severity and mortality among US Veterans. *PLoS One* 2021;16(4):e0248080.
38. Hwang AY, **Smith SM**. U.S. Trends in Prescription Nonsteroidal Anti-inflammatory Drug Use Among Patients with Cardiovascular Disease, 1988–2016. *Pharmacotherapy* 2021;41(3):247-56.
39. Cardel MI, Chi X, Min YI, Sims M, Musani S, Dulin A, Gravlee CC, **Smith SM**, DeBoer MD, Gurka MJ. Experiences of Discrimination are Associated with Worse Metabolic Syndrome Severity among African Americans in the Jackson Heart Study. *Ann Behav Med* 2021;55(3):266-79.
40. Mehanna M, Chen YE, Gong Y, Handberg E, Roth B, De Leon J, **Smith SM**, Harrell JG, Cooper-DeHoff RM. Optimizing precision of hypertension care to maximize blood pressure control (OPTI-BP): A pilot study utilizing a smartphone app to incorporate plasma renin activity testing. *Clin Trans Sci* 2020;14(2):617-24.
41. Sava RI, **Smith SM**, Chen Y, Taha Y, Gong Y, Keeley EC, Cooper-Dehoff RM, Pepine CJ, Handberg EM. Optimal systolic blood pressure and reduced long-term mortality in older hypertensive women with prior coronary events – an analysis from INVEST. *Int J Cardiol Hypertens* 2020;7:100052.
42. Keeley EC, Villanueva M, Chen YE, Gong Y, Handberg EM, **Smith SM**, Pepine CJ, Cooper-DeHoff RM. Attended vs Unattended Blood Pressure Measurement: A Randomized Comparison in Patients with Cardiovascular Disease. *J Clin Hypertens* 2020; 22(11):1987-1992.
43. Desai R, Dietrich EA, Park H, **Smith SM**. Out-of-Pocket Payment for Ambulatory Blood Pressure Monitoring Among Commercially-Insured in the United States. *Am J Hypertens* 2020;33(11):999-1002.
44. Desai R, Dietrich EA, Park H, **Smith SM**†. Trends in Ambulatory Blood Pressure Monitoring Use for Confirmation or Monitoring of Hypertension and Resistant Hypertension Among the Commercially-Insured in the U.S., 2008-2017. *Int J Cardiol Hypertens* 2020;6:100033.
45. Dawwas GH, Dietrich EA, Davis K, **Smith SM**, Park H. Comparative effectiveness and safety of direct acting oral anticoagulants and warfarin in patients with venous thromboembolism and active cancer: An observational-based analysis. *Clin Ther* 2020;42(9):e161-e176.
46. Dawwas GK, Leonard CE, Garg M, Vouri SM, **Smith SM**, Park H. Twelve-year trends in pharmacologic treatment of type 2 diabetes among patients with heart failure in the United States. *Diabetes Obes Metab* 2020;22(4):705-710.
47. Rowe CM, **Smith SM**, Cooper-DeHoff RM, Hogan W. The development of a drug classification system for antihypertensive medications utilizing electronic health record based data. *J Med Internet Res: Med Inform* 2020;8(2):e14777.
48. **Smith SM**, Winterstein AG, Pepine CJ, Cooper-DeHoff RM. Thiazide Exposure and Cardiovascular Risk in Type 2 Diabetes: A Point of Clarification. *Hypertension* 2020;75:e2-e5.
49. Dawwas G, **Smith SM**, Dietrich EA, Lo-Ciganic WH, Park H. Comparative Effectiveness and Safety of Apixaban Compared to Warfarin in Patients with Venous Thromboembolism. *Am J Health-Syst Pharm* 2020;77(3):188-195.



50. **Smith SM**, Gurka MJ, Winterstein AG, Handberg E, Pepine CJ, Cooper-DeHoff RM. Redefining resistant hypertension: A comparison of cardiovascular risk associated with the 2018 versus 2008 American Heart Association definitions for resistant hypertension. *Circ Cardiovasc Qual Outcomes* 2020;13:e005979.
51. Dietrich EA, Desai R, Garge M, Park H, **Smith SM**†. Reimbursement of Ambulatory Blood Pressure Monitoring in the U.S. Commercial Insurance Marketplace. *J Clin Hypertens* 2020;22(1):6-15.
52. Brown JD, **Smith SM**, Strotmeyer ES, Kritchevsky SB, Gill TM, Blair SN, Fielding RA, Buford TW, Pahor M, Manini TM. Comparative effects of ACE inhibitors and ARBs on response to a physical activity intervention in older adults: results from the Lifestyle Interventions for Elders (LIFE) study. *J Gerontol A Biol Sci Med Sci* 2020;75(5):1010-1016.
53. Sava RI, Chen YE, Gong Y, **Smith SM**, Cooper-DeHoff RM, Pepine CJ, Handberg EM. Relationship between risk and the spectrum of coronary artery disease in hypertensive women: An analysis from the International Verapamil SR/trandolapril Study (INVEST). *J Women's Health (Larchmt)* 2020;29(2):158-166.
54. **Smith SM**, Gurka MJ, Winterstein AG, Pepine CJ, Cooper-DeHoff RM. Incidence, prevalence and predictors of treatment-resistant hypertension with intensive blood pressure lowering. *J Clin Hypertens* 2019;21(6):825-834.
55. Dawwas GK, **Smith SM**, Park H. Cardiovascular outcomes of sodium glucose cotransporter-2 inhibitors in patients with type 2 diabetes. *Diabetes Obes Metab* 2019;21:28–36.
56. **Smith SM**, Gurka MJ, Calhoun DA, Gong Y, Pepine CJ, Cooper-DeHoff RM. Optimal systolic blood pressure target in resistant and non-resistant hypertension: A pooled analysis of patient-level SPRINT and ACCORD-BP data. *Am J Med* 2018;131:1463–1472.
57. Hwang AY, Dave C, **Smith SM**†. Use of prescription medications that potentially interfere with blood pressure control among patients with hypertension or treatment-resistant hypertension. *Am J Hypertens* 2018;31(12):1324-1331. (Featured by Reuters news: <https://www.reuters.com/article/us-health-hypertension/many-people-take-drugs-that-interfere-with-their-blood-pressure-pills-idUSKBN1L22AQ>)
58. Hwang AY, Carris NW, Dietrich EA, Gums JG, **Smith SM**†. Evaluation of SAME-TT<sub>2</sub>R<sub>2</sub> score on predicting success with extended-interval warfarin monitoring. *Ann Pharmacother* 2018;52(11):1085-1090.
59. Dawwas GK, **Smith SM**, Park H. Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists. *Cardiovasc Diabetol* 2018;17:102.
60. Gong Y, **Smith SM**, Handberg E, Pepine CJ, Cooper-DeHoff RM. Intensity of blood pressure lowering on adverse cardiovascular outcomes in nondiabetics and prediabetics: An analysis of the Systolic Blood Pressure Intervention Trial (SPRINT). *J Clin Hypertens (Greenwich)* 2018; 20(4):620-624.
61. **Smith SM**, McAuliffe K, Hall JM, McDonough CW, Gurka MJ, Robinson TO, Sacco RL, Pepine CJ, Shenkman E, Cooper-DeHoff RM. Hypertension in Florida: An Analysis of Data from the OneFlorida Clinical Data Research Network. *Prev Chronic Dis* 2018;15:170332.
62. Wokhlu A\*, **Smith SM**\*, Gong Y, Handberg EM, Elgendy IY, Bavry AA, Cooper-DeHoff RM, Pepine CJ. Mortality implications associated with lower diastolic blood pressure when systolic pressure is reduced to new goals: Long-term follow-up of hypertensive patients with coronary artery disease in US cohort of International Verapamil (SR)-Trandolapril Study (INVEST). *J Hypertens* 2018;36(2):419-27. (\*Co-first authors)

63. Tsai T, Kroehl ME, **Smith SM**, Thompson AM, Dai I, Trinkley KE. Efficacy and safety of twice- versus once-daily dosing of lisinopril for hypertension. *J Clin Hypertens (Greenwich)* 2017;19:868-73.
64. Hwang AY, Dave C, **Smith SM**†. Trends in antihypertensive medication use among U.S. patients with resistant hypertension, 2008-2014. *Hypertension* 2016;68:1349-54.
65. **Smith SM**, Huo T, Gong Y, Handberg E, Gulati M, Bairey Merz CN, Pepine CJ, Cooper-DeHoff RM. Mortality risk associated with resistant hypertension among women: Analysis from three prospective cohorts encompassing the spectrum of women's heart disease. *J Women's Health* 2016;25(10):996-1003.
66. Carris NW, Hwang AY, **Smith SM**, Taylor JR, Sando K, Powell J, Rosenberg EI, Zumberg MS, Gums JG, Dietrich EA, Vogel Anderson K. Patient satisfaction with extended-interval warfarin monitoring. *J Thromb Thrombolysis* 2016;42(4):486-493.
67. **Smith SM**, Carris NW, Dietrich ED, Gums JG, Uribe L, Coffey C, Gums TH, Carter BL. Physician-pharmacist collaboration versus usual care in treatment-resistant hypertension. *J Am Soc Hypertens* 2016;10(4):307-17.
68. Carris NW, Ghushchyan V, Libby AM, **Smith SM**†. Health-related quality of life in persons with apparent treatment-resistant hypertension on at least four antihypertensives. *J Hum Hypertens* 2016;30:191-6.
69. **Smith SM**, Hasan M, Huebschmann AG, Penaloza R, Schorr-Ratzlaff W, Sieja A, Roscoe N, Trinkley KE. Physician acceptance of a physician-pharmacist collaborative treatment model for hypertension management in primary care. *J Clin Hypertens (Greenwich)* 2015;17(9):686-691.
70. Carris NW, Spinelli A, Pierini D, Taylor J, Anderson K, Sando K, Powell J, Rosenberg E, Zumberg M, **Smith SM**, Gums JG, Dietrich E. Feasibility of extended-interval follow-up for patients receiving warfarin. *Cardiovasc Ther* 2015;33:98-103.
71. Rosenwasser R, Shah NK, **Smith SM**, Wen X, Gong Y, Nichols WW, Turner S, Chapman AB, Boerwinkle E, Johnson JA, Epstein BJ. Baseline predictors of central aortic blood pressure: A PEAR substudy. *J Am Soc Hypertens* 2014;8(3):152-8.
72. **Smith SM**, Huo T, Johnson BD, Vittner V, Kelsey SF, Thompson DV, Bairey Merz CN, Pepine CJ, Cooper-DeHoff RM. Cardiovascular and mortality risk of apparent resistant hypertension in women with suspected myocardial ischemia: A report from the NHLBI-sponsored WISE study. *J Am Heart Assoc* 2014;3:e000660.
73. **Smith SM**, Gong Y, Handberg E, Messerli FH, Bakris GL, Ahmed A, Bavry AA, Pepine CJ, Cooper-DeHoff RM. Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension. *J Hypertens* 2014;32:635-43.
74. **Smith SM**, Campbell JD. Cost-effectiveness of renin-guided treatment of hypertension. *Am J Hypertens* 2013;26:1303-10. (Chosen as "Editor's Choice" for its issue)
75. Evans G, Sutton DR, Dajani LH, Magee JS, Silva RA, Roura MF, Wadud K, Purcell JA, Travaglini S, Segel SA, Sultan S, Roffman MS, Ayad SS, Borja-Hart NL, **Smith SM**. A novel endocrinology-based wellness program to reduce medication expenditures and improve glycemic outcomes. *Diabetes Metab Syndr* 2013;7(2):87-90.
76. **Smith SM**, Gong Y, Turner ST, Cooper-DeHoff RM, Beitelshes AL, Chapman AB, Boerwinkle E, Bailey K, Johnson JA, Gums JG. Blood pressure responses and metabolic effects of hydrochlorothiazide and atenolol. *Am J Hypertens* 2012;25:359-65.



77. Motycka C, Kesgen C, **Smith SM**, Alvarez E, Jones K. Potential benefits of warfarin monitoring by a clinical pharmacist in a long term care facility. *J Thromb Thrombolysis* 2012;33:173-7.
78. Shah NK, **Smith SM**, Nichols WW, Lo MC, Ashfaq U, Satish P, Johnson JA, Epstein BJ. Carvedilol reduces aortic wave reflection and improves left ventricular/vascular coupling: A comparison with atenolol (CENTRAL Study). *J Clin Hypertens (Greenwich)* 2011;13:917-24.
79. **Smith SM**, Anderson SD, Wen S, Gong Y, Turner ST, Cooper-DeHoff RM, Schwartz GL, Bailey K, Chapman A, Hall KL, Feng H, Boerwinkle E, Johnson JA, Gums JG. Lack of Correlation Between Thiazide-Induced Hyperglycemia and Hypokalemia: Subgroup Analysis of Results from the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) Study. *Pharmacotherapy* 2009;29(10):1157-65.

Submitted:

80. Keshwani S, Smith KM, Winterstein AG, Gurka MJ, Walsh MG, Libby A, Hogan W, Pepine CJ, Cooper-DeHoff RM, **Smith SM**†. Disparities in Initial Antihypertensive Intensity by Sex, Race and Ethnicity in Newly-Treated Hypertension Patients. Submitted to *Am J Hypertens*, 2024.
81. Zapata RD, Rechdan M, Brinkley L, Louis-Jacques A, Modave F, **Smith SM**, Manini T, Wen T, Shenkman E, Lemas DJ. The Evolving Landscape of Biomedical Informatics and Machine Learning for Postpartum Hypertension: A Scoping Review. Submitted to *Am J Obstet Gynecol*, 2024.
82. Morris EJ, Lo-Ciganic WH, Daniels MJ, Segal R, Vouri SM, **Smith SM**†. Trajectories of xanthine oxidase inhibitor use and cardiovascular outcomes in older adults. Submitted to *Circ Cardiovasc Qual Outcomes*, 2024.
83. Jingzhi Y, Gauen AM, Zmora R, Petito LC, Kho AN, **Smith SM**, Allen NB. Patient predictors of combination therapy as first-line treatment: The All of Us Research Program (AOURP) Registry. Submitted to *J Am Heart Assoc*, 2024.
84. Tang H, Zhang B, Lu Y, Donahoo WT, Ospina NS, Kotecha P, Lu Y, Tong J, **Smith SM**, Rosenberg EI, Kimmel SE, Bian J, Guo J, Chen Y. Assessing the Benefit-Risk Profile of Newer Glucose-Lowering Drugs: Systematic Review and Network Meta-Analysis of Randomized Outcome Trials. Submitted to *Lancet Diabetes & Endocrinology*, 2024.
85. Dasa O, Handberg EM, Dey D, Sarder P, Lo MC, Tamarappoo BK, **Smith SM**, Shaw LJ, Bairey Merz CN, Pepine CJ. QUIET WARRIOR – Rationale and Design: an Ancillary Study to The Women’s Ischemia Trial to Reduce Events in Nonobstructive CAD (WARRIOR). Submitted to *Amer Heart J*, 2024

**Scientific Statements**

1. Carey RM, Calhoun D, Bakris G, Brook RD, Daugherty SL, Dennison-Himmelfarb C, Egan BM, Flack JM, Gidding SS, Judd E, Lackland DT, Laffer CL, Newton-Cheh C, **Smith SM**, Taler SJ, Textor SC, Turan T, White WB. 2018 American Heart Association Scientific Statement on Resistant Hypertension: Detection, Evaluation and Management. *Hypertension*, 2018;72(5):e53-e90.

**Review Articles (peer-reviewed)**

1. Piszczatoski CR, **Smith SM**†. Pharmacological considerations when treating hypertensive patients for osteoarthritis. *Expert Opin Pharmacother* 2022;23(15):1673-1676. INVITED REVIEW

2. Piszczański CR, **Smith SM**†. Fixed-dose combination amlodipine-celecoxib for treatment of hypertension and osteoarthritis pain: an up-to-date evaluation. *Expert Opin Pharmacother* 2021;22(11):1381-5. INVITED REVIEW
3. Garland S, **Smith SM**, Gums JG. Erenumab: A First-in-Class Monoclonal Antibody for Migraine Prevention. *Ann Pharmacother* 2019;53(9):933-9.
4. **Smith SM**, Cooper-DeHoff RM. Fixed-dose combination amlodipine/celecoxib (Consensi™) for hypertension and osteoarthritis. *Am J Med* 2019;132(2):172-174. INVITED REVIEW
5. Garland SG, DeRemer C, **Smith SM**, Gums JG. Betrixaban: A new oral factor Xa inhibitor for extended venous thromboembolism prophylaxis in high-risk hospitalized patients. *Ann Pharmacother*, 2018;52(6):554-61. INVITED REVIEW
6. Hwang AY, Dietrich EA, Pepine CJ, **Smith SM**†. Resistant Hypertension: Mechanisms and Treatment. *Curr Hypertens Rep* 2017;19:56. INVITED REVIEW
7. Carris NW, **Smith SM**†. Quality of life in treatment-resistant hypertension. *Curr Hypertens Rep* 2015;17(8):578. INVITED REVIEW
8. VanderWeide L, **Smith SM**, Trinkley KE. A systematic review of the efficacy of venlafaxine for the treatment of fibromyalgia. *J Clin Pharm Ther* 2015;40(1):1-6.
9. **Smith SM**. Epidemiology, prognosis, and treatment of resistant hypertension. *Pharmacotherapy* 2013;33(10):1071-86.
10. Nuffer W, **Smith SM**, Trinkley KE. Integrating “virtual reality” to expand the public health role of community pharmacists. *J Am Pharm Assoc* 2013;53:152-8.
11. **Smith SM**, Meyer M, Trinkley KE. Phentermine/topiramate (Qsymia®) for the treatment of obesity. *Ann Pharmacother* 2013;47:340-9.
12. Bovio J, **Smith SM**†, Gums JG. Dabigatran etexilate: A novel oral thrombin inhibitor for thromboembolic disease. *Ann Pharmacother* 2011;45:603-14.
13. **Smith SM**, Gums JG. Antivirals for influenza: Strategies for use in pediatrics. *Pediatr Drugs* 2010;12(5):285-99.
14. Epstein BJ, **Smith SM**, Choksi R. Recent changes in the landscape of combination RAS blockade. *Expert Rev Cardiovasc Ther* 2009;7(11):1373-84.
15. **Smith SM**, Gums JG. Fexofenadine: Biochemical, pharmacodynamics and pharmacokinetic properties and its unique role in allergic disorders. *Expert Opin Drug Metab Toxicol* 2009;5(7):813-822.

### Editorials, Commentaries, & Letters to the Editor

1. Cooper-DeHoff RM, **Smith SM**. Medication Adherence – Still the Holy Grail. *J Am Heart Assoc* 2022; 12(4):e028688. INVITED EDITORIAL
2. **Smith SM**, Cooper-DeHoff RM. Acetaminophen-Induced Hypertension: Where have all the “safe” analgesics gone? *Circulation* 2022;145(6):424-6. INVITED EDITORIAL

3. Guo J, **Smith SM**†. Newer drug treatments for type 2 diabetes: Guidance developed in partnership with patients recommends a risk based approach. *BMJ* 2021;373:n1171. **INVITED EDITORIAL**
4. **Smith SM**. SGLT2 inhibitors and kidney outcomes in the real world. *BMJ* 2020;369:m1584. **INVITED EDITORIAL**
5. Hwang AY, **Smith SM**†. Partnering with pharmacists to reduce cardiovascular risk in outpatient settings. *J Am Heart Assoc* 2019;8:e014705. **INVITED EDITORIAL**
6. **Smith SM**. The Reply: “Optimal Systolic Blood Pressure Target in Resistant Hypertension”. *Am J Med* 2019;132(7):e624-e625.
7. **Smith SM**. ARB superiority over ACE inhibitors in Coronary Heart Disease: An Alternative Viewpoint. *Pharmacotherapy* 2019;39(2):204-6.
8. **Smith SM**. Resistant hypertension and susceptible outcomes: Exploring the benefits of aggressive blood pressure control. *J Clin Hypertens (Greenwich)* 2015;18(1):40-42. **INVITED EDITORIAL**
9. **Smith SM**, Cooper-DeHoff RM. Home blood pressure monitoring with patient-initiated antihypertensive drug titration reduces blood pressure in high-risk patients with hypertension. *Evid Based Med* 2015;20(2):58. **INVITED EDITORIAL**
10. **Smith SM**, Pepine CJ, Cooper-DeHoff RM. Reply to “Resistant hypertension revisited: Definition and true prevalence.” *J Hypertens* 2014;32:1547.
11. **Smith SM**. Thiazide diuretics. *N Engl J Med* 2010;362(7):659-60.

#### **Book Chapters (peer-reviewed)**

1. Vascimini A, **Smith SM**, Gums JG. Osteoarthritis. In: Chisholm-Burns MA, Schwinghammer TL, Malone PM, Kolesar JM, Bookstaver B, Lee K, eds. *Pharmacotherapy Principles & Practice*. 7<sup>th</sup> ed. New York, NY: McGraw-Hill; 2024 [in press].
2. Dasa O, **Smith SM**, Pepine CJ. Hypertension in Ischemic Heart Disease. In *Hypertension: A Companion to Braunwald's Heart Disease*. 4<sup>th</sup> ed. Philadelphia, PA: Elsevier; 2024: 363-76.
3. Monahan C, **Smith SM**, Gums JG. Cushing Syndrome. In: Schwinghammer TL, Koehler JM, Borchert JS, Park S, Slain DS, eds. *Pharmacotherapy Casebook: A Patient-Focused Approach*. 12<sup>th</sup> ed. New York, NY: McGraw-Hill; 2023.
4. **Smith SM**, Piszczatoski C, Gums JG. Adrenal Gland Disorders. In: DiPiro JT, Yee GC, Ellingrod VL, Haines ST, Nolin TD, Posey LM. *Pharmacotherapy: A Pathophysiologic Approach*. 12<sup>th</sup> ed. New York, NY: McGraw-Hill; 2023: 1267-87.
5. Piszczatoski C, **Smith SM**, Gums JG. Osteoarthritis. In: Chisholm-Burns MA, Schwinghammer TL, Malone PM, Kolesar JM, Bookstaver B, Lee K, eds. *Pharmacotherapy Principles & Practice*. 6<sup>th</sup> ed. New York, NY: McGraw-Hill; 2022: 967-78.
6. Garland S, **Smith SM**, Gums JG. Cushing Syndrome. In: Schwinghammer TL, Koehler JM, Borchert JS, Park S, Slain DS, eds. *Pharmacotherapy Casebook: A Patient-Focused Approach*. 11<sup>th</sup> ed. New York, NY: McGraw-Hill; 2020: 239-40.

7. **Smith SM**, Garland S, Gums JG. Adrenal Gland Disorders. In: DiPiro JT, Yee GC, Ellingrod VL, Haines ST, Nolin TD, Posey LM. Pharmacotherapy: A Pathophysiologic Approach. 11<sup>th</sup> ed. New York, NY: McGraw-Hill; 2020: 1291-1312.
8. **Smith SM**. Antihypertensive pharmacology. In: Lackland DT, et al. Comprehensive Guide on Hypertension. Dallas, TX: American Heart Association; 2020. Comprehensive curriculum and continuing education activity available online at: <https://learn.heart.org/lms/activity?@curriculum.id=-1&@activity.id=7086643&@activity.bundleActivityId=-1>
9. Dietrich EA, Rubin D, **Smith SM**†. Osteoarthritis. In: Katz M, Matthias K, Chisholm-Burns MA. Pharmacotherapy Principles & Practice Study Guide: A Case-Based Care Plan Approach. 5<sup>th</sup> ed. New York, NY: McGraw-Hill; 2020.
10. Trinkley KE, **Smith SM**. Applying Literature to Patient Care. In: Aparasu RR, Sherer JT, Bentley JP. Principles of Research Design and Drug Literature Evaluation. 2<sup>nd</sup> ed. New York, NY: McGraw-Hill; 2019:223-30.
11. Garland S, Carris NW, **Smith SM**†. Osteoarthritis. In: Chisholm-Burns MA, Schwinghammer TL, Malone PM, Kolesar JM, Bookstaver B, Lee K, eds. Pharmacotherapy Principles & Practice. 5<sup>th</sup> ed. New York, NY: McGraw-Hill; 2019:903-13.
12. **Smith SM**, Dietrich EA, Sando KR. Treatment-resistant hypertension. In: Dong BJ, Elliott DP, eds. Ambulatory Care Self-Assessment Program, 2018 Book 1. Cardiology Care. Lenexa, KS: American College of Clinical Pharmacy, 2018:151-73.
13. Hwang AY, **Smith SM**, Gums JG. Cushing Syndrome. In: Schwinghammer TL, Koehler JM, Borchert JS, Park S, Slain DS, eds. Pharmacotherapy Casebook: A Patient-Focused Approach. 10<sup>th</sup> ed. New York, NY: McGraw-Hill; 2017.
14. Hwang AY, **Smith SM**, Gums JG. Hypothalamic, Pituitary and Adrenal Diseases. In: Tisdale JE and Miller DA (eds.). Drug-Induced Diseases: Prevention, Detection and Management. 3<sup>rd</sup> ed. Bethesda, MD: American Society of Health-System Pharmacists; 2018:729-755.
15. Hwang AY, **Smith SM**, Gums JG. Adrenal Gland Disorders. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. Pharmacotherapy: A Pathophysiologic Approach. 10<sup>th</sup> ed. New York, NY: McGraw-Hill; 2017:1207-1226.
16. **Smith SM**, Pepine CJ. Hypertension in Ischemic Heart Disease. In Hypertension: A Companion to Braunwald's Heart Disease. 3<sup>rd</sup> ed. Philadelphia, PA: Elsevier; 2017:288-297.
17. Dietrich EA, Michaudet C, **Smith SM**†. Osteoarthritis. In: Katz M, Matthias K, Chisholm-Burns MA. Pharmacotherapy Principles & Practice Study Guide: A Case-Based Care Plan Approach. 4<sup>th</sup> ed. New York, NY: McGraw-Hill; 2016:239-240.
18. Carris N, **Smith SM**, Gums JG. Osteoarthritis. In: Chisholm-Burns MA, Schwinghammer TL, Wells BG, Malone PM, Kolesar JM, DiPiro JT. Pharmacotherapy Principles & Practice. 4<sup>th</sup> ed. New York, NY: McGraw-Hill; 2016:889-899.
19. Dietrich EA, **Smith SM**, Gums JG. Cushing's Syndrome. In: Schwinghammer TL, Koehler JM. Pharmacotherapy Casebook: A Patient-Focused Approach. 9<sup>th</sup> ed. New York, NY: McGraw-Hill; 2014:88-1-88-3.

20. Dietrich EA, **Smith SM**, Gums JG. Adrenal Gland Disorders. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. *Pharmacotherapy: A Pathophysiologic Approach*. 9<sup>th</sup> ed. New York, NY: McGraw-Hill; 2014:1217-1236.
21. Trinkley KE, **Smith SM**. Applying Literature to Patient Care. In: Aparasu RR, Sherer JT, Bentley JP. *Principles of Research Design and Drug Literature Evaluation*. 1<sup>st</sup> ed. Boston, MA: Jones & Bartlett; 2014:323-335.
22. **Smith SM**, Vogel Anderson K. Adrenal and Pituitary Disorders. In: Dong BJ, Elliott DP, eds. *Ambulatory Care Self-Assessment Program, 2014 Book 1. Endocrinology/Rheumatology*. Lenexa, KS: American College of Clinical Pharmacy, 2014:92-120.
23. **Smith SM**, Gums JG, Dietrich E. Osteoarthritis. In: Katz M, Matthias K, Chisholm-Burns MA. *Pharmacotherapy Principles & Practice Study Guide: A Case-Based Care Plan Approach*. 3<sup>rd</sup> ed. New York, NY: McGraw-Hill; 2013;265-7.
24. **Smith SM**, Dietrich E, Gums JG. Osteoarthritis. In: Chisholm-Burns MA, Schwinghammer TL, Wells BG, Malone PM, Kolesar JM, DiPiro JT. *Pharmacotherapy Principles & Practice*. 3<sup>rd</sup> ed. New York, NY: McGraw-Hill. 2013;1041-53.
25. **Smith SM**, Gums JG. Cushing's Syndrome. In: Schwinghammer TL, Koehler JM. *Pharmacotherapy Casebook: A Patient-Focused Approach*. 8<sup>th</sup> ed. New York: McGraw-Hill; 2011: 233-5.
26. **Smith SM**, Gums JG. Adrenal Gland Disorders. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. *Pharmacotherapy: A Pathophysiologic Approach*. 8<sup>th</sup> ed. New York: McGraw-Hill; 2011: 1327-44.
27. **Smith SM**. Osteoarthritis. In: Chisholm-Burns MA, Katz M, Matthias K. *Pharmacotherapy Principles & Practice Study Guide: A Case-Based Care Plan Approach*. 1<sup>st</sup> ed. New York, NY: McGraw-Hill; 2011: 247-9.
28. **Smith SM**, Epstein BJ, Gums JG. Osteoarthritis. In: Chisholm-Burns MA, Schwinghammer TL, Wells BG, Malone PM, Kolesar JM, DiPiro JT. *Pharmacotherapy Principles & Practice*. 2<sup>nd</sup> ed. New York, NY: McGraw-Hill; 2010: 997-1009.

### **Non-Peer-Reviewed**

1. **Smith SM**. At the Forefront of U.S. Health and Policy: The 2014-2016 National Academy of Medicine Fellowship. *ACCP Report* 2016;35(11):14-15. Available electronically at: <http://www.accp.com/docs/report/1116.pdf>.

### **Abstracts/Presentations**

#### Presented/Published:

1. McFarlane A, Staras SA, Mullis MD, Hansen N, Alacevich C, Bylund CL, Duncan G, Shelnutt K, Harrell G, **Smith SM**, Fisher CL. Targeting Implementation Strategies Aimed at Reducing Hypertension with Low-Income, Food-Insecure Adults. Poster presentation at the 17th Annual Conference on the Science of Dissemination and Implementation in Health, December 8-11, 2024, Washington, DC, USA.
2. Hall JM, Xu J, Walsh MG, Cho HD, Harrell G, **Smith SM**, Staras SA. Unsupervised Learning Using EHR Data to Detect Distinct Subphenotypes of Hypertension. Poster presentation at the OneFlorida+ Clinical



Research Network and UF CTSI Conference: Transforming Patient-Centered Health Care Delivery through an AI-enabled Learning Health System, Amelia Island, Florida, USA, September 5-6, 2024.

3. Ndai A, **Smith SM**, Reise R. Analyzing Factors Affecting Length of Emergency Department Stay in Patients with Hemophilia. Poster presentation ISPOR 2024 Annual Meeting, Atlanta, Georgia, USA, May 5-8, 2024.  
*\*\*Top 5% Finalist for the ISPOR 2024 Research Presentation Awards.*
4. Chamberlain AM, Cooper-Dehoff RM, Lin F, Fontil V, Shaw KM, Smith M, Carton T, O'Brien EC, Modrow MF, Wozniak G, Rakotz M, **Smith SM**, Pletcher MJ. Trends in Blood Pressure Control With the Covid-19 Pandemic, 2017 to 2022: A Study of 17 US Health Systems in the PCORnet® Blood Pressure Control Laboratory. Accepted for oral platform presentation at the American Heart Association 2024 Epi/Lifestyle Scientific Sessions, Chicago, IL, March 19, 2024.
5. Smith KM, Morris E, Ndai A, Keshwani S, Kulkarni P, Schmidt S, Pepine C, Vouri SM, **Smith SM**. High-throughput Screening Detects Thiazide-induced Prescribing Cascades. Poster presentation at American Heart Association 2023 Hypertension Scientific Sessions, Boston, MA, September 7-10, 2023.
6. Smith KM, Morris E, Ndai A, Keshwani S, Kulkarni P, Schmidt S, Pepine C, Vouri SM, **Smith SM**. High-throughput sequence symmetry analysis to detect angiotensin-converting enzyme inhibitors (ACEI) induced prescribing cascades. Poster presentation at American Heart Association 2023 Hypertension Scientific Sessions, Boston, MA, September 7-10, 2023.
7. Smith KM, Morris E, Ndai A, Keshwani S, Kulkarni P, Schmidt S, Pepine C, Vouri SM, **Smith SM**. High-throughput sequence symmetry analysis to detect angiotensin-receptor blockers (ARB) induced prescribing cascades. Poster presentation at American Heart Association 2023 Hypertension Scientific Sessions, Boston, MA, September 7-10, 2023.
8. Smith KM, Winterstein AG, Gurka MJ, Walsh MG, Keshwani S, Libby A, Hogan W, Pepine CJ, Cooper-DeHoff RM, **Smith SM**. Time to First Follow-up Visit for Patients with Newly Treated Hypertension Among Florida Medicaid and Medicare Recipients. Poster presentation at American Heart Association 2023 Hypertension Scientific Sessions, Boston, MA, September 7-10, 2023.
9. Du F, **Smith SM**, Bress AP, Jiao T. The Impact of De-escalating Antihypertensive Drugs: A Secondary Analysis of the Systolic Blood Pressure Intervention Trial (SPRINT). Oral platform presentation at American Heart Association 2023 Hypertension Scientific Sessions, Boston, MA, September 7-10, 2023.
10. **Smith SM**, Xu J, Hall J, Walsh MG, Cho HD, Harrell G, Staras SAS. Unsupervised Learning Using EHR Data to Detect Distinct Subphenotypes of Hypertension. Oral platform presentation at American Heart Association 2023 Hypertension Scientific Sessions, Boston, MA, September 7-10, 2023.
11. Keshwani S, Smith KM, Winterstein AG, Gurka MJ, Walsh MG, Libby A, Hogan W, Pepine CJ, Cooper-DeHoff RM, **Smith SM**. Provider and Health System Level Variability in Initial Antihypertensive Intensity: A Mixed Modeling Approach in Newly Treated Patients with Hypertension. Poster presentation at American Heart Association 2023 Hypertension Scientific Sessions, Boston, MA, September 7-10, 2023.
12. Hernandez-Con P, Wilson DL, **Smith SM**, Norse AB, Park H. The cascade of care in individuals screened for hepatitis C virus infection in emergency departments. Poster presentation at ICPE 2023 Annual Meeting, Halifax, Nova Scotia, Canada, August 23-27, 2023.
13. Ndai A, **Smith SM**, Svensson MK, Vouri SM, Reise R. The role of anticoagulants clinics in anticoagulant therapy initiation for incident atrial fibrillation. Oral presentation at the ISPOR 2023 Annual International Meeting. Boston, MA, USA. May 7-10, 2023. Abstract published in *Value in Health* 2023;26(6 Suppl. 1):S13.  
*\*\*Top 5% Finalist for the ISPOR 2023 Research Presentation Awards.*

**\*\*Best student oral podium presentation of ISPOR 2023.**

14. Huang W, Ahmed MM, **Smith SM**, Hasan MM, Rouhizadeh M, Bian J, Kimmel S, Guo J. Trajectories of Sacubitril/Valsartan Adherence Among Medicare Beneficiaries with Heart Failure. Poster presentation at the ISPOR 2023 Annual Meeting, Boston, MA, USA, May 7-10, 2023. Abstract published in *Value in Health* 2023;26(6 Suppl. 1):S191.

**\*\*Top 5% Finalist for the ISPOR 2023 Research Presentation Awards**

15. Riaz M, **Smith SM**, Dietrich EA, Winchester DE, Guo J, Park H. Comparative effectiveness and costs of sacubitril/valsartan versus angiotensin receptor blockers in heart failure with preserved ejection fraction. Poster presentation at ISPOR 2023 Annual Meeting, Boston, MA, USA, May 9, 2023. Abstract published in *Value in Health* 2023;26(6 Suppl. 1):S40.
16. Riaz M, **Smith SM**, Dietrich EA, Winchester DE, Guo J, Park H. Utilization trends of pharmacotherapies among patients with heart failure with preserved ejection fraction. Poster presentation at ISPOR 2023 Annual Meeting, Boston, MA, USA, May 9, 2023. Abstract published in *Value in Health* 2023;26(6 Suppl. 1):S41.
17. Riaz M, **Smith SM**, Dietrich EA, Winchester DE, Guo J, Park H. Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors among patients with heart failure with preserved ejection fraction: A real-world study. Poster presentation at ISPOR 2023 Annual Meeting, Boston, MA, USA, May 7, 2023. Abstract published in *Value in Health* 2023;26(6 Suppl. 1):S23.
18. Kulkarni PJ, Morris EJ, Walsh MG, Schmidt S, Pepine CJ, Vouri SM, **Smith SM**. Using Drug Package Insert Data to Identify Statin-related Prescribing Cascades – An Evaluation of Findings from Side Effect Resource (SIDER) and Commercial Claims Data. Poster presentation at the ISPOR 2023 Annual Meeting, Boston, MA, USA, May 7-10, 2023. Abstract published in *Value in Health* 2023;26(6 Suppl. 1):S165.
19. Keshwani S, Smith KM, Winterstein AG, Gurka MJ, Walsh MG, Libby AM, Hogan W, Pepine CJ, Cooper-DeHoff RM, **Smith SM**. Predictors of initial antihypertensive intensity in newly-treated patients with hypertension. Poster presentation at the ISPOR 2023 Annual Meeting, Boston, MA, USA, May 7-10, 2023. Abstract published in *Value in Health* 2023;26(6 Suppl. 1):S246.
20. Chen WH, Li Y, Chen A, Allen JM, Guo Y, **Smith SM**, Bian J, Guo J. Social Determinants of Health and Newer Glucose-lowering Drugs Adoption among US Medicare Beneficiaries with Type 2 Diabetes. Poster presentation at ISPOR 2023 Annual Meeting, Boston, MA, USA, May 7-10, 2023.
21. Wang G, Morris EJ, Walsh MG, Schmidt S, Pepine CJ, Vouri SM, **Smith SM**. Modifiable statin characteristics associated with potential statin-related prescribing cascades. Poster presentation at the 2023 Annual ISPE Midyear meeting, Reykjavik, Iceland, April 23-25, 2023.
22. Mehanna M, Gong Y, McDonough CW, **Smith SM**, Gums JG, Chapman AB, Johnson JA, McIntyre L, Cooper-DeHoff RM. Integrated Metabolomics Analysis Reveals Mechanistic Insights into the Ancestral Differences in Plasma Renin Activity Among Patients with Hypertension and Thiazide Diuretics Blood Pressure Lowering Effects. Poster presentation at ASCPT 2023 Annual Meeting, Atlanta, GA, USA, Mar 22-24, 2023. Abstract available in: *Clin Pharmacol Ther* 2023;113(Suppl. S1):S91.
23. Smith KM, Winterstein AG, Gurka MJ, Walsh MG, Keshwani S, Libby A, Hogan W, Pepine CJ, Cooper-DeHoff RM, **Smith SM**. Initial antihypertensive prescribing in relation to blood pressure among Medicaid and Medicare recipients. Abstract accepted for presentation at the 2023 American Heart Association EPI/Lifestyle Meeting, Boston, MA, USA, Feb 28 – Mar 3, 2023. Abstract published in *Circulation* 2023;147:AP394.



24. Vouri SM, Morris EJ, Walsh M, Hochleitner L, Muschett MR, Agalliu J, Dempsey A, Schmidt S, Pepine CJ, **Smith SM**. Screening for statin-related prescribing cascades using high-throughput prescription sequence symmetry analysis. Oral platform presentation at the 38<sup>th</sup> International Conference for Pharmacoepidemiology and Therapeutic Risk Management (ICPE) 2022, Copenhagen, Denmark, August 24-28, 2022.
25. Wang G, **Smith SM**, Vouri SM. Prescribing cascade relics: An evaluation of continued potassium supplementation following diuretic discontinuation in patients previously experiencing a loop diuretic hypokalemia-potassium prescribing cascade. Poster presentation at the 38<sup>th</sup> International Conference for Pharmacoepidemiology and Therapeutic Risk Management (ICPE) 2022, Copenhagen, Denmark, August 24-28, 2022.
26. Chen WH, Li Y, Allen JM, Shao H, Donahoo WT, **Smith SM**, Guo J. Geographic Variation and Racial Disparities in Newer Glucose-lowering Drugs Adoption among US Medicare Beneficiaries with Type 2 Diabetes. Oral platform presentation at the 38th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE) 2022, Copenhagen, Denmark, August 24-28, 2022.
27. Dasa O, Bai C, Mardini M, **Smith SM**, Cooper-DeHoff-RM, Handberg E, Pepine CJ. Machine learning prediction of blood pressure variability. Poster presentation at the American College of Cardiology 2022 annual meeting, Washington, DC, March, 2022. Abstract available in *J Am Coll Cardiol* 2022;79(9\_Supplement):1581.
28. Mehanna M, Gong Y, McDonough CW, **Smith SM**, Gums JG, Chapman AB, Johnson JA, McIntyre L, Cooper-DeHoff RM. Metabolomic Associations with Genetic African Ancestry in Hypertensive Patients. Poster presentation at the UF College of Pharmacy Research Showcase, Gainesville, FL, February, 2022.
29. Hwang AY, **Smith SM**. Seasonal variations in blood pressure control among US adults with hypertension, 2011-2018. Poster presentation at American Heart Association Epi/Lifestyle 2022 Scientific Sessions, March, 2022. Abstract published in *Circulation* 2022;145:AP035.
30. Chamberlain AM, Cooper-DeHoff RM, Fontil V, Nilles EK, Shaw KM, Smith M, Maeztu C, Todd J, Carton T, O'Brien EC, Faulkner Modrow M, Wozniak G, Rakotz M, Sanches E, **Smith SM**, Pletcher MJ. Disruption in blood pressure control with the COVID-19 pandemic: A study of 24 US health systems in the PCORnet Blood Pressure Control Laboratory. Oral presentation in the Late Breaking Science session, American Heart Association Scientific Sessions [Virtual] November 13-15, 2021. Abstract published in *Circulation* 2021;144(25):e567-8.
31. Riaz M, Dietrich EA, **Smith SM**, Pepine CJ, Park H. Sacubitril/valsartan versus aldosterone antagonists on all-cause and heart failure-related hospitalization in patients with systolic heart failure. Poster presentation at 2021 International Conference for Pharmacoepidemiology (virtual). Abstract available in *Pharmacoepidemiol Drug Saf* 2021;30(S1):210.
32. Dasa OD, **Smith SM**, Howard G, Cooper-DeHoff RM, Handberg EM, Pepine CJ. Association Between Short-term Visit-to-Visit Blood Pressure Variability and Long-term Mortality Among Patients with Coronary Artery Disease. Poster presentation at ACC.21 Conference, May 2021. Abstract available in *J Am Coll Cardiol* 2021;77(18\_Supplement\_1):1646.
33. Desai R, **Smith SM**, Mohandas R, Park H. Comparative safety of epoetin versus darbepoetin in prevention of major adverse cardiovascular events in patients undergoing hemodialysis. Presented as Spotlight Poster at the International Conference on Pharmacoepidemiology 2020 All Access Meeting (live meeting cancelled due to COVID-19), September 2020. Abstract available in *Pharmacoepidemiol Drug Saf* 2020;29(S3):138.

34. Morris E, Jiang X, Pepine CJ, **Smith SM**, Vouri SM. Evaluation of the beta-blocker – edema – loop diuretic prescribing cascade among adults: A prescription sequence symmetry analysis. Poster presentation at the International Conference on Pharmacoepidemiology 2020 All Access Meeting (live meeting cancelled due to COVID-19), September 2020. Abstract available in *Pharmacoepidemiol Drug Saf* 2020;29(S3):475.
35. Taha Y, Xu K, **Smith SM**, Handberg EM, Bairey Merz CN, Pepine CJ. Electrocardiographic (ECG) predictors of major adverse cardiac events in women with ischemia and no obstructive coronary artery disease (INOCA): From the Women's Ischemia Syndrome Evaluation (WISE). Abstract accepted for poster presentation at European Society of Cardiology Congress 2020 (live meeting cancelled due to COVID-19), August 29 – September 2, 2020. Abstract available in *Eur Heart J* 2020;41(Supplement\_2):3188.
36. Vouri SM, **Smith SM**, Jiang X, Morris EJ, Usmani SA, Manini T, Solberg LM, Pepine C, Winterstein AG. Evaluation of the hydralazine -anxiousness – benzodiazepine prescribing cascade among older adults. Poster presentation at the American Society of Geriatrics 2020 Annual Meeting, Long Beach, CA, USA (live meeting cancelled due to COVID-19). Abstract available in *J Am Geriatr Soc* 2020;68(S1):S223.
37. Vouri SM, **Smith SM**, Jiang X, Morris EJ, Usmani SA, Manini T, Solberg LM, Pepine C, Winterstein AG. Evaluation of the non-dihydropyridine calcium channel blocker – edema – loop diuretic prescribing cascade among older adults. Poster presentation at the American Society of Geriatrics 2020 Annual Meeting, Long Beach, CA, USA (live meeting cancelled due to COVID-19). Abstract available in *J Am Geriatr Soc* 2020;68(S1):S223.
38. Desai R, Park H, **Smith SM**. Risk of obstructive sleep apnea in adults with treatment resistant hypertension: a population-based cohort study using administrative claims data. Poster presentation at the UF College of Pharmacy Research Showcase, February 10<sup>th</sup>, 2020, Gainesville, FL, USA.
39. Hwang AY, **Smith SM**. U.S. National Estimates of Prescription Nonsteroidal Anti-inflammatory Drugs Among Patients with Cardiovascular Disease. Poster presentation at the American Heart Association EPI/Lifestyle 2020 Annual Scientific Sessions, March 3<sup>rd</sup>, 2020, Phoenix, AZ, USA. Abstract available in *Circulation* 2020;141:AP372.
40. Smith K, Dawwas GK, **Smith SM**. Trends in the use of Antihypertensive Medications among Pregnant Women with Chronic Hypertension. Poster presentation at the 2019 American College of Clinical Pharmacy Annual Meeting, October 28, 2019, New York, NY, USA.
41. Holmes HR, Li Q, Xu K, Kim S, Sumner E, Keeley E, Handberg E, **Smith SM**, Raizada M, Pepine CJ, Cooper-DeHoff RM. A pilot study of antihypertensive medication adherence trends by sex and drug class. Oral platform presentation at 2019 American Heart Association Hypertension Scientific Sessions, September 5-8, New Orleans, LA, USA. Abstract published in *Hypertension* 2019;74:A032.
42. Villanueva M, Chen YE, **Smith SM**, Gong Y, Handberg EM, Pepine CJ, Keeley EC, Cooper-DeHoff RM. Attended Versus Unattended Blood Pressure Measurement in Patients with Cardiovascular Disease: Does it Matter? Oral platform presentation at 2019 American Heart Association Hypertension Scientific Sessions, September 5-8, New Orleans, LA, USA. Abstract published in *Hypertension* 2019;74:A026.
43. **Smith SM**, Desai R, Dietrich ED, Park H. Trends in ambulatory and home blood pressure monitoring use for confirmation of hypertension or resistant hypertension among commercially-insured in the U.S., 2008-2017. Poster presentation at 2019 American Heart Association Hypertension Scientific Sessions, September 5-8, New Orleans, LA, USA. Abstract published in *Hypertension* 2019;74:AP2067.
44. Mehanna M, Chen YE, Gong Y, Handberg E, Roth B, De Leon J, Hough A, Parra D, **Smith SM**, Harrell JG, Cooper-DeHoff RM. Optimizing precision of hypertension care to maximize blood pressure control (OPTI-BP): A pilot study. Poster presentation at 2019 American Heart Association Hypertension Scientific Sessions, September 5-8, New Orleans, LA, USA. Abstract published in *Hypertension* 2019;74:AP181.

45. Sava RI, Chen YE, Gong Y, Taha YK, **Smith SM**, Cooper-DeHoff RM, Keeley EC, Pepine CJ, Handberg EM. Do hypertensive women with coronary artery disease benefit from lowering systolic blood pressure under 130 mmHg? Long-term mortality in the International Verapamil SR-trandolapril Study (INVEST). Poster presentation at 2019 European Society of Cardiology Annual Meeting, August 31- September 4, 2019, Paris, France. Abstract published in *Eur Heart J* 2019;40(Suppl 1):3598.
46. Dawwas GK, **Smith SM**†. Risk of inflammatory bowel disease with sodium glucose co-transporter-2 inhibitors compared to dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes. Oral platform presentation at 2019 International Conference on Pharmacoepidemiology (ICPE) Annual Meeting, August 24-28, 2019, Philadelphia, PA, USA. Abstract published in *Pharmacoepidemiol Drug Saf* 2019;28(Suppl 2):38.
47. Dawwas GK, **Smith SM**, Park H. Risk of lower extremity amputation with sodium glucose cotransporter-2 inhibitors compared to sulfonylureas and dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes. Poster presentation at 2019 Society of Epidemiologic Research Annual Meeting, June 18-21, 2019, Minneapolis MN, USA.
48. Holmes HR, Li Q, Xu K, Kim S, Sumner E, Keeley E, Handberg E, **Smith SM**, Raizada M, Pepine CJ, Cooper-DeHoff RM. A pilot study of antihypertensive medication adherence trends by sex and drug class. Poster presentation at UF Center for Integrative Cardiovascular and Metabolic Disease Early Career Member Research Showcase, June 6, 2019, Gainesville, FL, USA.
49. Villanueva M, Chen YE, **Smith SM**, Gong Y, Handberg EM, Pepine CJ, Keeley EC, Cooper-DeHoff RM. Attended Versus Unattended Blood Pressure Measurement in Patients with Cardiovascular Disease: Does it Matter? Poster presentation at UF Center for Integrative Cardiovascular and Metabolic Disease Early Career Member Research Showcase, June 6, 2019, Gainesville, FL, USA.
50. Desai R, Dietrich E, Mahek G, Park H, **Smith SM**†. Reimbursement of Ambulatory Blood Pressure Monitoring in the Commercial Insurance Marketplace. Poster presentation at 2019 ISPOR Annual Meeting, May 18-22, 2019, New Orleans, LA, USA. Abstract published in *Value Health* 2019;22(Suppl 2):S125.
51. Desai R, Dietrich E, Mahek G, Park H, **Smith SM**†. The Out-of-Pocket Burden of Ambulatory Blood Pressure Monitoring: A United States Perspective in the Commercial Insurance Marketplace. Poster presentation at 2019 ISPOR Annual Meeting, May 18-22, 2019, New Orleans, LA, USA. Abstract published in *Value Health* 2019;22(Suppl 2):S123.
52. Dawwas GK, **Smith SM**†. Risk of acute kidney injury with SGLT2 inhibitors compared to sulfonylureas in patients with type 2 diabetes. Poster presentation at 2019 European Causal Inference Meeting, March 27-29, 2019, Bremen, Germany.
53. Hwang AY, **Smith SM**, Dietrich EA, Carris NW, Gums JG. Evaluation of SAME-TT2R2 score on predicting anticoagulation control with extended-interval warfarin monitoring. Poster presentation at the American Pharmacists Association (APhA) Annual Meeting & Exposition, March 23, 2019, Seattle, WA, USA. Abstract published in *J Am Pharm Assoc* 2019;59(3).
54. Brown J, Kritchevsky SB, Burford T, Gill T, Strotmeyer E, **Smith SM**, Pahor M, Manini TM. ACE inhibitors and ARBs influence on mobility outcomes in older adults: Results from the LIFE trial. Poster presentation at Gerontological Society of America 2018 Annual Meeting, November 14, 2018, Boston, MA, USA. Abstract published in *Innovation in Aging* 2018;2(Suppl 1):892.
55. Deininger KM, Hirsch JD, Graveline SA, Feist A, **Smith SM**, Reich JA, LaFleur J, Ambardekar AV, Lindenfeld J, Aquilante CL. Relationship between patient-perceived treatment burden and health-related quality of life in heart transplant recipients. Abstract presented at the International Society for Heart & Lung

Transplantation 2018 Annual Meeting, April 11-14, Nice, France; and published in *J Heart Lung Transplant* 2018;37(4):S351.

56. Smith DM, Weitzel KW, Elsey AR, Wake DT, Gong Y, Duong BQ, Newsom K, **Smith SM**, Starostik P, Clare-Salzler MJ, Schmidt SO, Johnson JA, Filingim R, Cavallari LH. Outpatient CYP2D6 genotype-supported opioid therapy: A prospective trial. Abstract presented at American Society of Human Genetics 2018 Annual Meeting and published in *Clin Pharmacol Ther* 2018;103(S1):S8. (\*Selected for the ASCPT Presidential Trainee Award).
57. Hwang AY, **Smith SM**, Dietrich EA, Carris NW, Gums JG. Evaluation of SAME-TT2R2 score on predicting anticoagulation control with extended-interval warfarin monitoring. Poster Presentation at the American College of Clinical Pharmacy 2017 Annual Meeting, October 8, 2017, Phoenix, AZ, USA. Abstract published in *Pharmacotherapy* 2017;37(12):e174.
58. Bejjanki H, Gong Y, Willis D, Siler-Marsiglio K, Handberg E, Haight D, **Smith S**, Pepine C, Cooper-DeHoff R. Perception of Blood Pressure Control and Satisfaction with Hypertension Care in the Rural Setting. Abstract presented at the American Heart Association's Hypertension 2017 Scientific Sessions, September 15, 2017, San Francisco, CA, USA. Abstract published in *Hypertension* 2017;70(Suppl 1):AP220.
59. Deininger KM, Hirsch JD, Graveline SA, Feist A, **Smith SM**, Reich JA, LaFleur J, Ambardekar AV, Lindenfeld J, Aquilante CL. Relationship between patient-perceived treatment burden and medication adherence in heart transplant patients. Oral presentation at the International Society for Heart & Lung Transplantation (ISHLT) 2017 Annual Meeting and Scientific Sessions, April 5-8, 2017, San Diego, CA, USA. Abstract published in *J Heart Lung Transplant* 2017;36(4):S152.
60. Wokhlu A, Gong Y, Cooper-DeHoff RM, **Smith SM**, Handberg EM, Pepine CJ. Relationship between diastolic blood pressure and all-cause mortality with lower systolic blood pressure among hypertensive coronary artery disease patients: Long-term follow-up of the US cohort of the International Verapamil-SR-Trandolapril Study (INVEST). Poster Presentation at the American College of Cardiology (ACC) 2017 Annual Scientific Session & Expo, March 17-19, 2017, Washington D.C., USA. Abstract published in *J Am Coll Cardiol* 2017;69(11):1685.
61. Hwang AY, Dave C, **Smith SM**. Use of Medications that Potentially Interfere with Blood Pressure Control among Patients with Resistant Hypertension on  $\geq 4$  Antihypertensive Drugs. Poster presentation at:
  - a. 2016 American College of Clinical Pharmacy Annual Meeting, October 24<sup>th</sup>, 2016, Hollywood, FL, USA (Original presentation).
  - b. 2017 UF College of Pharmacy Research Showcase, February 17<sup>th</sup>, 2017, Gainesville, FL, USA (Encore presentation).
  - c. 2017 UF College of Medicine Celebration of Research, February 27<sup>th</sup>, 2017, Gainesville, FL, USA (Encore presentation).
62. Aquilante CL, Hirsch JD, LaFleur J, Reich J, **Smith SM**. Patient-perceived treatment burden following heart transplantation. Platform presentation at 2016 Skaggs Biomedical Research Symposium, August 4-5, 2016, Pocatello, ID, USA.
63. Deininger KM, Reich JA, Hirsch JD, Graveline S, LaFleur J, **Smith SM**, Ambardekar AV, Lindenfeld J, Aquilante CL. Qualitative assessment of patient-perceived treatment burden following cardiac transplantation. Poster presentation at:
  - a. 2016 American Transplant Congress, June 11-15, 2016, Boston, MA, USA (Original presentation). Abstract published in *Am J Transplant* 2016;16(suppl 3):553 and <http://www.atcmeetingabstracts.com/abstract/qualitative-assessment-of-patient-perceived-treatment-burden-following-cardiac-transplantation/>.
  - b. 2016 American College of Clinical Pharmacy Annual Meeting, October 23-25, 2016, Hollywood, FL, USA (Encore presentation).



64. **Smith SM**, Hwang AY, Dave C. Trends in antihypertensive medication use among U.S. patients with resistant hypertension, 2008-2013. Poster presentation at:
- 2016 American Society of Hypertension Annual Meeting, May 14<sup>th</sup>, 2016, New York, NY, USA. Abstract available in *J Am Soc Hypertens* 2016;10(4S):e36 (Original presentation)
  - 2016 Community Health & Family Medicine Research Showcase, June 23<sup>rd</sup>, 2016, Gainesville, FL (Encore presentation)
  - 2016 American College of Clinical Pharmacy Annual Meeting, October 25<sup>th</sup>, 2016, Hollywood, FL, USA (Encore presentation)
65. Farland M, Ryan S, Ramachandran N, **Smith SM**. An electronic gallery walk in a high enrollment pharmacy population health course. Technology Showcase Demonstration and Poster Presentation at Team-Based Learning Collaborative 2016 Annual Meeting, March 3-5, 2016, Albuquerque, NM, USA.
66. Tsai T, Kroehl M, **Smith SM**, Thompson A, Trinkley K. Efficacy and safety of twice- versus once-daily dosing of lisinopril for the treatment of hypertension. Poster presentation at the 2015 American Society of Health-System Pharmacists (ASHP) Midyear Annual Meeting, December 7<sup>th</sup>, 2015, New Orleans, LA, USA.
67. Carris NW, **Smith SM**, Taylor JR, Sando K, Powell J, Hwang A, Gums JG, Dietrich E, Vogel Anderson K. Anticoagulation-related quality of life associated with extended-interval monitoring: A pre-specified analysis of the FADE-OUT study. Poster presentation at the 2015 American College of Clinical Pharmacy (ACCP) Global Conference on Clinical Pharmacy, October 20<sup>th</sup>, 2015, San Francisco, CA, USA. Abstract published in *Pharmacotherapy* 2015;35(11):e271.
68. Dietrich E, **Smith SM**, Gums JG. A Novel Revenue-Generating Pharmacy-Led Transitions of Care Program. Platform & Poster presentation at the 2015 American College of Clinical Pharmacy (ACCP) Global Conference on Clinical Pharmacy, October 19<sup>th</sup>, 2015, San Francisco, CA, USA. Abstract published in *Pharmacotherapy* 2015;35(11):e223-e224.
69. Trujillo JM, Malhotra JV, **Smith SM**, Franson KL. Establishing inter-rater reliability of two patient-centered communication rubrics with international faculty evaluators. Poster presentation at the 2015 American Association of Colleges of Pharmacy (AACP) Annual Meeting, July 11-15, 2015, Washington D.C., USA.
70. Trujillo JM, Franson KL, **Smith SM**, Trujillo TC. Establishing the inter-rater reliability of two patient-centered communication evaluation rubrics. Poster presentation at the 2015 American Association of Colleges of Pharmacy (AACP) Annual Meeting, July 11-15, 2015, Washington D.C., USA.
71. Shute K, Kodsi B, Samraj G, Malaty J, Carris N, **Smith SM**. Establishing and integrating a multidisciplinary anticoagulation clinic into an academic-based residency program. Scholarly Topic Roundtable Presentation at the Society of Teachers of Family Medicine 2015 annual meeting, April 25<sup>th</sup>-29<sup>th</sup>, 2015, Orlando, FL, USA.
72. Huo T, **Smith SM**, Pepine CJ, Gong Y, Handberg E, Gulati M, Bairey Merz CN, Cooper-DeHoff RM, Chi YY. Data and statistical challenges in pooled analysis of clustered survival data from multiple clinical studies. Poster presentation at the 70<sup>th</sup> Deming Conference on Applied Statistics, December 8-12, 2014, Atlantic City, NJ, USA.
73. **Smith SM**, Ghushchyan V, Libby AM. Direct medical expenditures and healthcare utilization associated with resistant hypertension in the United States. Poster presentation at the American Heart Association 2014 Scientific Sessions, November 16, 2014, Chicago, IL, USA. Abstract available in *Circulation* 2014;130:A20369 and [http://circ.ahajournals.org/content/130/Suppl\\_2/A20369.abstract](http://circ.ahajournals.org/content/130/Suppl_2/A20369.abstract).

74. **Smith SM**, Huo T, Gong Y, Handberg E, Gulati M, Bairey Merz CN, Pepine CJ, Cooper-DeHoff RM. Mortality risk associated with apparent treatment-resistant hypertension among women. Poster presentation at:
- American Heart Association 2014 Scientific Sessions, November 16, 2014, Chicago, IL, USA. Abstract available in *Circulation* 2014;130:A17677 and [http://circ.ahajournals.org/content/130/Suppl\\_2/A17677.abstract](http://circ.ahajournals.org/content/130/Suppl_2/A17677.abstract). (Original presentation)
  - UF College of Medicine 2015 Celebration of Research, February 9, 2015, Gainesville, FL, USA. (Encore presentation)
75. **Carris NW**, Taylor J, Anderson KV, Sando K, Spinelli A, Elliott J, Powell J, Pierini DC, Cogan P, **Smith SM**, Gums JG, Dietrich E. Feasibility of extended duration follow-up for patients receiving warfarin. Poster presentation at:
- American College of Clinical Pharmacy 2014 Annual Meeting, October 14, 2014, Austin, TX, USA. Abstract available in *Pharmacotherapy* 2014;34(10):e254. (Original presentation)
  - UF College of Medicine 2015 Celebration of Research, February 9, 2015, Gainesville, FL, USA. (Encore presentation)
76. **Smith SM**, Hasan M, Huebschmann A, Penaloza R, Schorr-Ratzlaff W, Sieja A, Trinkley K. Physician engagement and acceptance of collaborative treatment of hypertension in primary care. Platform and poster presentation at the American College of Clinical Pharmacy 2014 Annual Meeting, October 13, 2014, Austin, TX, USA. (2<sup>nd</sup> runner up for 2014 ACCP Annual Meeting "Great Eight" Best Paper competition). Abstract available in *Pharmacotherapy* 2014;34(10):e182.
77. Hirsch J, Watanabe J, LaFleur J, **Smith SM**, Aquilante C, Libby A. Medication Regimen Complexity Index (MRCI): The Skaggs Research Cascade. Poster presentation at the 2014 Skaggs Biomedical Research Symposium, August 14, 2014, Missoula, MT, USA.
78. Aquilante CL, Hirsch JD, LaFleur J, Libby AM, Lindenfeld J, Page RL, **Smith SM**. Predictors of medication non-adherence following heart transplantation: the role of medication regimen complexity and patient-perceived treatment burden. Poster presentation at the 2014 Skaggs Biomedical Research Symposium, August 14, 2014, Missoula, MT, USA.
79. **Smith SM**, Ghushchyan V, Libby AM. Health-related quality of life in persons with apparent treatment-resistant hypertension taking at least four antihypertensives. Poster presentation at:
- American Society of Hypertension 2014 Annual Meeting, May 18, 2014, New York, NY, USA. Abstract available in *J Am Soc Hypertens* 2014;8(4S):e84. (Original presentation)
  - American College of Clinical Pharmacy 2014 Annual Meeting, October 13, 2014, Austin, TX, USA. (Encore presentation)
80. Borja-Hart N, **Smith SM**, Wooten A, Lukawski T, Epstein BJ. Simulating Framingham risk reductions to assess applicability as a global study endpoint: Report from the P.A.T.H. Steering Committee. Poster presentation at the American Society of Health-System Pharmacists (ASHP) 2012 Annual Midyear Meeting, December 2012, Las Vegas, NV, USA. Abstract available at: <http://www.ashp.org/DocLibrary/Abstract-Archive/MCM12-Poster-Abstracts.pdf>.
81. **Smith SM**, Borja-Hart N, Wooten A, Epstein BJ. Discordance between regression-derived and ATP III table-derived Framingham 10-year risk. Poster presentation at the American College of Clinical Pharmacy 2012 Annual Meeting, October 24<sup>th</sup>, 2012, Kissimmee, FL. Abstract available in *Pharmacotherapy* 2012;32(10):e184-e185.
82. Trinkley K, Moore G, Nair K, **Smith SM**. A reimbursement model through a University's self-insurance for ambulatory care clinical pharmacy services. Poster presentation at the American College of Clinical Pharmacy 2012 Annual Meeting, October 24<sup>th</sup>, 2012, Kissimmee, FL. Abstract available in *Pharmacotherapy* 2012;33(10):e253.

83. **Smith SM**, Borja-Hart NL, Wooten A, Lukawski T, Shah NK, Epstein BJ. Simulating Framingham risk reductions to assess applicability as a global study endpoint: Report from the P.A.T.H. Steering Committee. Poster presentation at the Florida Society of Health-System Pharmacists (FSHP) 2012 Annual Meeting, August 2012, Orlando, FL, USA.
84. Shah NK, Epstein BJ, Lo M, Ashfaq U, Satish P, **Smith SM**, Nichols WW. Carvedilol reduces aortic wave reflection and improves left ventricular/vascular coupling compared to atenolol: The CENTRAL Study. Poster presentation at the University of Florida Annual College of Pharmacy Research Showcase, February 2011, Gainesville, FL, USA.
85. **Smith SM**, Antonio S, Barkley P, Dequesada A, Dodd V, Drucker J, Giuliano A, Manion E, Obesso D, Cook RL. The HPV Oral Prevalence Investigation (HOP-IN) Study: Rationale & Design. Poster presentation at Emerging Pathogen Institute 2011 Research Day, February 10<sup>th</sup>, 2011, Gainesville, FL, USA.
86. Gums JG, **Smith SM**, Tyrol K, Patel R, Adelman DN, Ng V, Pratt LE. A national antibiotic surveillance program: 3 year follow-up study. Poster presentation at ICAAC 50<sup>th</sup> Annual Meeting, September 13<sup>th</sup>, 2010, Boston, MA, USA.
87. **Smith SM**, Gums JG, Alessandrini J, Kaufman D, Ng V. Can an individualized educational stewardship program affect prescribing patterns and reduce antimicrobial resistance? Poster presentation at IDSA 47<sup>th</sup> Annual Meeting, October 30<sup>th</sup>, 2009, Philadelphia, PA, USA.
88. Nichols WW, **Smith SM**, Epstein BJ. Elevated wasted left ventricular pressure effort and reflected wave amplitude in treated hypertensives. Poster presentation at American Society of Hypertension Annual Meeting, San Francisco, CA. May 7<sup>th</sup>, 2009. Abstract available in *J Clin Hyperten* 2009;11(4):A18.
89. **Smith SM**, Anderson SD, Cooper-DeHoff RM, Feng H, Bailey K, Turner ST, Chapman A, Johnson JA, Gums JG. Correlation of thiazide-induced potassium changes with glucose. Poster presentation at:
  - a. ACCP 2008 Annual Meeting, Louisville, KY. October 21<sup>st</sup>, 2008. Abstract available in *Pharmacotherapy* 2008;28:138e. (Original presentation)
  - b. ACCP 2009 Spring Meeting, Orlando, FL. April 25<sup>th</sup>, 2009. (Encore presentation)
  - c. UF College of Medicine Research Showcase, Gainesville, FL. April 28<sup>th</sup>, 2009. (Encore presentation)
90. **Smith SM**, Gums JG, Greaves R, Ng V. Outcomes Associated with the Implementation of a National Antibiotic Surveillance Program. Poster presentation at:
  - a. ICAAC/IDSA 2008 Annual Meeting, Washington, D.C. October 26<sup>th</sup>, 2008. (Original presentation)
  - b. ACCP 2009 Spring Meeting, Orlando, FL. April 25<sup>th</sup>, 2009. (Encore presentation)
  - c. UF College of Medicine Research Showcase, Gainesville, FL. April 28<sup>th</sup>, 2009. (Encore presentation)
91. **Smith SM**, Gums JG, Jermaine C, Ranka S. The Implications of Phenotypic Clustering on Predicting Future Trends of Antimicrobial Resistance Patterns. Poster presentation at:
  - a. ICAAC/IDSA 2008 Annual Meeting, Washington, D.C. October 26<sup>th</sup>, 2008. (Original presentation)
  - b. ACCP 2009 Spring Meeting, Orlando, FL. April 25<sup>th</sup>, 2009. (Encore presentation)

Submitted:

1. Riaz M, **Smith SM**, Guo J, Dietrich EA, Winchester DE, Park H. Comparative genitourinary safety of sodium glucose co-transporter-2 inhibitors among patients with heart failure with preserved ejection fraction. Abstract submitted to ISPOR 2024 Annual Meeting, Atlanta, Georgia, USA, May 5-8, 2024.



2. Yang S, Orlova Y, Park H, **Smith SM**, Guo Y, Lo-Ciganic W. Patient characteristics and medication use patterns among Medicare beneficiaries with migraine in the United States. Abstract submitted to ICPE 2023 Annual Meeting, Halifax, Nova Scotia, Canada, August 23-27, 2023.
3. Huang W, Kimmel SE, Ahmed MM, **Smith SM**, Hasan MM, Rouhizadeh M, Bian J, Guo J. The Impact of Contextual-Level Social Determinants of Health on Heart Failure Readmission and Mortality in Patients Hospitalized for Heart Failure. Abstract submitted to ICPE 2023 Annual Meeting, Halifax, Nova Scotia, Canada, August 23-27, 2023.
4. Alexander TJ, Carton T, Merritt G, **Smith SM**, Ahmad FS, Petito LC, Gauen AM, Kohli-Lynch CN, Allen NB. Hypertension in Young Adults: Social Determinants of Prevalence, Awareness, Treatment, and Control. Abstract submitted to AHA Hypertension 2024 Scientific Sessions, Chicago, IL, USA, September 5-8, 2024.

## **TEACHING**

**University of Florida** (2007 – 2011; 2014 – present)

College of Pharmacy

*Course Coordination:*

Measurement in Pharmaceutical Outcomes and Policy Research (PHA 6717). 2<sup>nd</sup>-3<sup>rd</sup> year PhD and MS students. Spring semesters (3 credit hours). Course co-coordinator (2024 – present). This semester-long course is an intermediate-level graduate course that expounds on theory and application of measurement in epidemiologic and outcomes research.

Pharmacoepidemiology and Drug Safety (PHA 5223). 3<sup>rd</sup> year PharmD students. Fall semesters (2 credit hours). Course leader (2023 – present). This 5-week courses uses team-based learning to provide an overview of fundamental concepts in pharmacoepidemiology and drug safety study design for students in the PharmD program.

Pharmacy & Population Health (PHA 5007). 1<sup>st</sup> year PharmD students. Fall semesters (2 credit hours). Course leader (2015 – 2020). This 5-week course uses team-based learning to provide an introduction to population health concepts and how pharmacists engage in population health activities.

Pharmacotherapy VI (PHA 5788). 4<sup>th</sup> year PharmD students. Spring semesters (2 credit hours). Overall course coordinator (2015 – 2018). Section co-coordinator (2008 – 2011). This 8-week course served as the capstone for the PharmD curricula, where students present cases and evidence-based therapeutic plans from patients seen during their rotations.

Ambulatory Care Clinical Rotations. July 2008 – June 2011; March 2014 – June 2016. Precept 15-18 students/year during 8-week Ambulatory Care required rotation or 4-week Ambulatory Care elective rotation.

*Lecturer:*

*Secondary data sources in POP research:* PHA 6265 – Introduction to Pharmaceutical Outcomes & Policy (Graduate program; 3 credit hours); 2021 – present

*Patient safety studies:* PHA 6265 – Introduction to Pharmaceutical Outcomes & Policy (Graduate program; 3 credit hours); 2023

*Measurement using EHR data:* PHA 6717 – Measurement in Pharmaceutical Outcomes & Policy Research (Graduate program; 3 credit hours); 2020 – 2023

*Gout and Hyperuricemia:* PHA 5788C – Patient Care VI (PharmD program; 3 credit hours); 2017.

*Glaucoma:* Pharmacotherapy II (PharmD program; 3 credit hours); 2008 – 2011.

*Depression:* Pharmacotherapy II (PharmD program; 3 credit hours); 2008 – 2011.

*Skin/soft tissue infections:* Pharmacotherapy III (PharmD program; 3 credit hours); 2008 – 2011.

*Upper and lower respiratory tract infections:* Pharmacotherapy III (PharmD program; 3 credit hours); 2008 – 2011.

*Vancomycin pharmacokinetics:* Pharmacotherapy V (PharmD program; 3 credit hours); 2007.

#### College of Medicine – Family Medicine Residency Program

Scholars Program. 2016 – 2018. Research/QI project mentor for 2<sup>nd</sup> and 3<sup>rd</sup> year Family Medicine physician residents.

#### College of Medicine – Physician Assistant Program

Pharmacotherapy. 2008 – 2011. Lecturer (Hypertension, Heart Failure, Diabetes, Infectious Diseases & Antibiotics, Antiviral/Antifungal/Antiparasitic Pharmacotherapy, Geriatric Pharmacotherapy, GI Pharmacotherapy, COPD/Asthma).

### **University of Colorado (2011 – 2014)**

#### School of Pharmacy

PHRD 5965, Patient-centered Communication 2. Course Coordinator (2013 – 2014); Approximately 160 students/semester; Course Coordinator and lectured approximately 4 hours/semester on prescription counseling and medication adherence assessment/motivational interviewing.

PHRD 8700, Advanced Pharmacy Practice Experience. May 2012 – December 2013. Precepted 1-2 students per 6-week rotation through Internal Medicine clinic.

#### School of Medicine

Ambulatory Care Clinical Elective. 2012 – 2013; Facilitated pharmacotherapy case discussions with 3<sup>rd</sup> year medical students for ~1 hour/month

**Residents/Fellows** (reverse chronological order)

1. Christie Monahan, PharmD (Family Medicine Fellow – UF), 2021 – 2023. Current position: Ambulatory Care Pharmacist, Cityblock Health, Greensboro, NC.
2. Christopher Piszczatoski, PharmD (Family Medicine Fellow – UF), 2019 – 2021. Current position: Clinical Specialist, Department of Community Health & Family Medicine, College of Medicine, University of Florida, Gainesville, FL.
3. Ghadeer Dawwas, PhD (Pharmaceutical Outcomes & Policy Fellow – UF), 2019. Current position: Assistant Professor of Medicine, College of Medicine, Vanderbilt University, Nashville, TN.
4. Scott Garland, PharmD (Family Medicine Fellow – UF), 2017 – 2019. Current position: Assistant Professor of Medicine, Department of Family Medicine, College of Medicine, Florida State University.
5. Andrew Hwang, PharmD, BCPS (Family Medicine Fellow – UF), 2015 – 2017. Current position: Associate Professor of Pharmacy, Massachusetts College of Pharmacy and Health Sciences, Boston, MA.
6. Nick Carris, PharmD, BCPS (Family Medicine Fellow - UF), 2014 – 2015. Current position: Associate Professor of Pharmacy, University of South Florida, Tampa, FL.
7. Michaela Hasan, PharmD (PGY-1 Community Pharmacy - CU), 2013 – 2014. Current position: Compounding Pharmacist, Denver, CO.
8. Allie Schroeder, PharmD (Clinical Outcomes Fellow – CU/Kaiser Permanente), 2013 – 2014. Current position: Clinical Pharmacist, Denver VAMC.
9. William (Mackie) King IV, PharmD, BCPS (PGY-2 Ambulatory Care - CU), 2012 – 2013. Current position: Clinical Pharmacist, New Hanover Regional Medical Center, Wilmington, NC.
10. Kelli Metz, PharmD (Pharmaceutical Outcomes Research Fellow - CU), 2012 – 2014. Current position: Clinical Services Pharmacist, Colorado Department of Health Care Policy and Financing, Denver, CO.
11. Kimberly Swanson, PharmD (PGY-1 Community Pharmacy - CU), 2012 – 2013. Current position: Clinical Sales Manager, King Soopers, Denver, CO.
12. Angie Thompson, PharmD, BCPS (PGY-2 Ambulatory Care - CU), 2011 – 2012. Current position: Assistant Professor of Pharmacy, University of Colorado, Aurora, CO.

**Graduate Committees** (reverse chronological order)

*Chair/Co-Chair (Major Advisor)*

1. Ngoc Thuy Tram (Tram) Nguyen, MS (PhD Candidate, Pharmaceutical Sciences–Pharmaceutical Outcomes Concentration), 2024 – present
2. Shu Niu, MS (PhD Candidate, Pharmaceutical Sciences–Pharmaceutical Outcomes Concentration), 2024 – present
3. Kayla Smith, PharmD (PhD Candidate, Pharmaceutical Sciences–Pharmaceutical Outcomes Concentration), 2022 – present
4. Asinamai Ndai, MS (PhD Candidate, Pharmaceutical Sciences–Pharmaceutical Outcomes Concentration), 2021 – present
5. Shailina Keshwani, MS (PhD Candidate, Pharmaceutical Sciences–Pharmaceutical Outcomes Concentration), 2020 – present

6. Earl J. Morris, PharmD, MPH, PhD (Pharmaceutical Sciences–Pharmaceutical Outcomes Concentration), 2019 – 2023. First position: Research Assistant Professor, Department of Pharmaceutical Outcomes & Policy, College of Pharmacy, University of Florida, Gainesville, FL.
7. Raj Desai, PhD (Pharmaceutical Sciences–Pharmaceutical Outcomes Concentration), 2018 – 2022. First position: Associate–Health Economics and Outcomes Research, Analysis Group, Boston, MA.

### *Member*

#### PhD Program

1. Wei-Han (William) Chen, MS (PhD Candidate, Pharmaceutical Sciences–Pharmaceutical Outcomes Concentration), 2023 – present
2. Priyanka Kulkarni (PhD Candidate, Pharmaceutical Sciences–Pharmaceutical Outcomes Concentration), 2022 – present
3. Ruben D. Zapata, MS (PhD Candidate, Medicine-Health Outcomes and Biomedical Informatics), 2023 – present. *\*External Member*
4. Wenxi Huang, MS (PhD Candidate, Pharmaceutical Sciences–Pharmaceutical Outcomes Concentration), 2023 – present
5. Matthew Muschett, PharmD (PhD Candidate, Pharmaceutical Sciences–Pharmaceutical Outcomes Concentration), 2023 – present
6. Eissa Jafari, PharmD, MS (PhD Candidate, Pharmaceutical Sciences–Clinical Sciences Concentration), 2022 – present
7. Seongkyeong Yang, MSPH (PhD Candidate, Pharmaceutical Sciences–Pharmaceutical Outcomes Concentration), 2021 – 2024.
8. Yimei Huang, PharmD (PhD Candidate, Pharmaceutical Sciences–Clinical Sciences Concentration), 2019 – 2023. First position: Clinical Pharmacist, UF Health
9. Munaza Riaz, PharmD, MPhil, PhD (Pharmaceutical Sciences–Pharmaceutical Outcomes Concentration), 2017 – 2022. First position: Postdoctoral fellow, University of Florida
10. Mai Mehanna, MS, PhD (Pharmaceutical Sciences–Clinical Sciences Concentration), 2019 – 2022.

#### MS Program

1. Pareeta Kotecha (Pharmaceutical Sciences–Pharmaceutical Outcomes Concentration), 2022 – 2024
2. Wei-Han (William) Chen (Pharmaceutical Sciences–Pharmaceutical Outcomes Concentration), 2021 – 2023
3. Wenxi Huang, MS (Pharmaceutical Sciences–Pharmaceutical Outcomes Concentration), 2021 – 2023

### **CLINICAL ACTIVITY**

2014 – 2016

Co-Director, Anticoagulation and Pharmacotherapy Consult Services, Family Medicine at Main St, UF Health

2012 – 2014	Director, Hypertension Clinic, University Medicine Lowry and University Medicine Anschutz, Division of Internal Medicine, Department of Medicine, School of Medicine, University of Colorado
2011 – 2014	Director, Pharmacotherapy Consult Service, University Medicine Lowry, Division of Internal Medicine, Department of Medicine, School of Medicine, University of Colorado
2012 – 2013	Member, PCMH Team of Champions, University Medicine, University of Colorado Hospital
2011 – 2012	Co-Director, <i>RxConsult</i> (CU self-insurance clinical pharmacy service), University of Colorado
2008 – 2011	Associate Director, Pharmacotherapy Consult Service, Family Medicine at 4 <sup>th</sup> Ave, University of Florida
2007 – 2008	Hospital Practice Resident, NF/SG Veteran's Affairs Hospital, Gainesville, FL

### **SPEAKING ENGAGEMENTS** (reverse chronological order)

1. *Practical Approaches to Managing Treatment-Resistant Hypertension*. American College of Cardiology 2024 Annual Meeting, Atlanta, GA, April 7, 2024.
2. *Treatment-Resistant Hypertension: Moving from Assessing Risk to Modifying Outcomes*. Seminar Series, College of Pharmacy, Mercer University, Atlanta, GA, November 2, 2022.
3. *Blood Pressure Controversies: The Central Nervous System and the Older Patient* (Session Chair), American Heart Association Hypertension Scientific Sessions 2019, New Orleans, LA, September 8, 2019.
4. *Impact of Recent U.S. Hypertension Guidelines on Treatment-Resistant Hypertension*, Department of Pharmaceutical Outcomes and Policy Seminar Series, University of Florida, Gainesville, FL, February 2019.
5. *Strategies for Managing Resistant Hypertension*, 2018 Clinical Reasoning Series in Ambulatory Care Pharmacy: It's Not a Sprint, It's a Marathon: Keeping up with Hypertension Management. American College of Clinical Pharmacy (ACCP) Global Conference on Clinical Pharmacy, Seattle, WA, October 22, 2018.
6. *Primary Care Track: The Evolving Landscape of Blood Pressure Guidelines Part 3: Special Situations*, Panel Discussant, American Heart Association Hypertension 2018 Scientific Sessions, Chicago, IL, September 8, 2018.
7. *Electronic Gallery Walks: An Excel Online solution for large enrollment classroom activities*, UF Interface 2018 Conference, University of Florida, Gainesville, FL, April 2018.
8. *The Rise and Fall of 'Resistant' Blood Pressure: Adverse Consequences & Clinical Approaches to Difficult-to-Treat Hypertension*, College of Pharmacy, University of Florida, Gainesville, FL, July 2016.
9. *Pharmacist-Physician Collaboration for Uncontrolled Treatment-Resistant Hypertension*. Community Health & Family Medicine Research Day, University of Florida, Gainesville, FL, June 2016.
10. *Adverse Outcomes and Clinical Approaches to Resistant Hypertension*. Pharmacotherapy & Translational Research Seminar Series, University of Florida, Gainesville, FL, March 2016.
11. *2015 New Investigator Award Seminar: Resistant Hypertension: Determinants, Outcomes, and Approaches to Blood Pressure Intransigence*, American College of Clinical Pharmacy Global Conference, San Francisco, CA, October 2015.

12. Fellowship Discussion, Student Residency Forum, College of Pharmacy, University of Florida, Gainesville, FL, September 2015.
13. Introductory Professional Pharmacy Experience Panel Discussion, College of Pharmacy, University of Florida, Gainesville, FL, November 2014.
14. *Physician Engagement and Acceptance of Collaborative Treatment of Hypertension in Primary Care*, American College of Clinical Pharmacy Annual Meeting, Austin, TX, October 2014.
15. *Resistant Hypertension: The Adverse Impact of Blood Pressure Intransigence*, Pharmacotherapy & Translational Research Seminar Series, University of Florida, Gainesville, FL, November 2013
16. *Resistant Hypertension: Current Treatment and the Road Ahead*, Pharmacotherapy & Translational Research Seminar Series, University of Florida, Gainesville, FL, November 2012
17. *Tuberculosis Screening and Testing Policies Among U.S. Universities: A cross-sectional survey of university student health care center directors*, Public Health Research Day, College of Public Health & Health Professions, University of Florida, Gainesville, FL, July 2011
18. *Central Aortic Blood Pressure Effects of Antihypertensive Therapies*, Pharmacotherapy & Translational Research/Center for Pharmacogenomics Seminar Series, University of Florida, Gainesville, FL, April 2011
19. *Thiazide-induced hypokalemia and hyperglycemia*, North Central Florida Society of Health Systems Pharmacists (NCFSHS) Meeting, Gainesville, FL, June 2010
20. *Antimicrobial Surveillance: Hindsight is not 20/20*, Pharmacotherapy & Translational Research/Center for Pharmacogenomics Seminar Series, University of Florida, Gainesville, FL, March 2010
21. *Thiazide-induced hypokalemia and dysglycemia: Comparing emergent data with old assumptions*, Pharmacotherapy & Translational Research/Center for Pharmacogenomics Seminar Series, University of Florida, Gainesville, FL, May 2009
22. *Outpatient Management of Chronic Heart Failure*, UF 2009 Primary Care Symposium CE Program, Gainesville, FL
23. *The changing landscape of heart failure: Translating emerging data into practice*, Ken Finger 2008 CE Program, University of Florida, Gainesville, FL, June 2008

## **SERVICE**

### **University of Florida (2014 – present)**

#### *University-wide*

2021 – 2022      Search Committee for Asst/Assoc/Full Prof (Health Determinants Committee),  
Artificial Intelligence Initiative, UF Health Science Center Colleges

#### *College of Pharmacy*

2019 – present      Ad hoc Grant Reviewer, UF PROSPER Clinical Research Grants  
2019 – 2020      Search Committee for Asst/Assoc Prof, Pharmaceutical Outcomes & Policy,  
Member



2019	32 <sup>nd</sup> Annual COP Research Showcase, <i>Poster Presentation Judge</i>
2018 – present	PharmD/MPH Joint Degree Program, <i>Coordinator</i>
2018 – 2019	Search Committee for Asst/Assoc Prof, Pharmaceutical Outcomes & Policy, <i>Member</i>
2017 – present	Faculty Advisor, PharmD Program
2017 – present	COP Exemplary Clinician Award selection committee, <i>Chair</i>
2016 – present	Faculty Awards Committee, <i>Member</i>
2017 – 2018	Search Committee for Community-Based Pharmacotherapy Division Head, <i>Chair</i>
2016 – 2018	Professionalism Committee, <i>Member</i>
2015	Search Committee for Pharmaceutical Outcomes & Policy Department Chair, <i>Member</i>
2015	28 <sup>th</sup> Annual COP Research Showcase, <i>Oral Presentation Judge</i>
2015	2015 Clinical Practice Strategic Planning Task Force (COP), <i>Member</i>
2014 – 2016	APPE Student Issues <i>ad hoc</i> committee, <i>Member</i>
2014 – 2015	Admissions Committee, <i>Member</i>

#### *College of Medicine*

2015 – 2018	CHFM Scholars Program, <i>Mentor</i>
2015 – 2016	Search Committee for CHFM Vice Chair for Research, <i>Member</i>
2014 – 2016	CHFM Research/QI Committee (COM), <i>Member</i>

#### *Clinical & Translational Science Institute*

2015 – 2018	Personalized Medicine Program Education Advisory Board, <i>Member</i>
-------------	---

#### **University of Colorado (2011 – 2014)**

2012 – 2014	Honors Program Committee, <i>Member</i>
2012 – 2014	Distance Degree Program Committee, <i>Member</i>
2013 – 2014	NTPD Instructor Search Committee (ad hoc), <i>Chair</i>
2013 – 2014	Faculty & Staff Accreditation Committee, <i>Member</i>

### **PROFESSIONAL ACTIVITY AND PUBLIC SERVICE**

#### **Alachua County Department of Health**

Pharmacy Lead, COVID-19 Mass Vaccination Clinic, April – May, 2021

#### **Grant Review Activities / Study Section**

##### *American Heart Association*

Reviewer, Fellowship Human Studies 1 committee (pre-doc and post-doc awards), November 2021, November 2024

##### *National Institutes of Health*



*Ad hoc* reviewer, Cancer, Heart and Sleep Epidemiology, Section B (CHSB) study section, October 2020, February 2021, June 2021, February 2022

### **Service and Membership in professional organizations**

U.S. CDC National Hypertension Control Roundtable, Founding Member, 2020 – present

U.S. Centers for Disease Control and Prevention (CDC), Division for Heart Disease & Stroke Prevention, Hypertension Control Meeting, Invited Participant, September 9<sup>th</sup>-10<sup>th</sup>, 2019, Atlanta GA

Consortium for Southeastern Hypertension Control, Member 2018 – 2023  
Board of Directors (term: 2019 – 2023)

International Society for Pharmacoepidemiology, Member, 2017 – present  
Abstract Reviewer, 2020 Spring ISPE Meeting, Orlando, FL

American College of Cardiology, Member, 2017 – present  
Member, Cardiovascular Team Section (2017 – present)  
Member, Prevention Section (2017 – present)  
Abstract Reviewer, 2023 Annual Meeting, New Orleans, LA

American Society of Hypertension, Member, 2012 – 2018 (reorganized within AHA Hypertension Council)

Member, Task Force for ASH Hypertension Specialists Designation Status for Qualified Non-physician Healthcare Providers (2013 – 2014) (*\*In this role, I helped lead development of a national certification program for primary care physicians and allied health professionals engaged in the management of hypertension*)

Founding Member, Examination Committee for ASH (now, American Hypertension Specialists Certification Program [AHSCP]) Certified Hypertension Clinician program (2014 – present)  
Item Writer, ASH Certified Hypertension Clinician Examination (2015 – present)

American Heart Association, Member, 2012 – present  
Member, Council for Hypertension (formerly, High Blood Pressure Research), 2012 – present  
Program Committee Member, Primary Care Track, AHA Hypertension Council/ASH Annual Meeting  
September 2017, San Francisco, CA  
September 2018, Chicago, IL  
September 2019, New Orleans, LA  
Expert Faculty (Antihypertensive Pharmacology), AHA Hypertension Study Guide

American College of Clinical Pharmacy, Member 2007 – present  
Member, Ambulatory Care PRN (2008 – present)  
Member, Research Process Committee (2015 – 2016)  
Member, Cardiology PRN (2011 – present)  
Member, Nominations Committee (2017 – 2018)  
Co-Chair, Nominations Committee (2018 – 2019)  
Member, Infectious Diseases PRN (2008 – 2011)

National Lipid Association, Member 2011 – 2014

American Association of Colleges of Pharmacy, Member, Pharmacy Practice Session, 2011 – present

National Interdisciplinary Primary Care Practice-Based Research Network, Member 2008 – 2011, 2014 – present

American Society of Health-Systems Pharmacists, Member 2007-2009

American Pharmacists Association, Member 2005 – 2008, 2011 – 2014, 2019 –

### Editor & Editorial Boards

2022 – Guest Editor (ad hoc), *American Heart Journal Plus*  
2021 – 2022 Guest Editor (special edition on deprescribing), *American Heart Journal Plus*  
2016 – present Editorial Board Member, *Pharmacotherapy*

### Journal Referee

2024 – present *JAMA Network Open*  
2023 – present *Gut*  
2022 – present *Circulation: Cardiovascular Quality and Outcomes*  
2020 – present *Circulation*  
2020 – present *Diabetes, Obesity and Metabolism*  
2019 – present *BMJ*  
2019 – present *Journal of the American College of Clinical Pharmacy (JACCP)*  
2019 – present *Journal of the American Heart Association (JAHA)*  
2018 – present *Expert Opinion on Pharmacotherapy*  
2018 – present *BMC Cardiovascular Disorders*  
2018 – present *Preventing Chronic Disease (CDC)*  
2018 – present *Vascular Health & Risk Management*  
2018 – present *Hypertension*  
2017 – present *BMJ Open*  
2016 – present *American Journal of Preventive Medicine*  
2015 – present *Journal of Human Hypertension*  
2015 – present *Journal of Clinical Hypertension*  
2015 – present *Obesity*  
2014 – present *PLoS One*  
2013 – present *Therapeutic Advances in Cardiovascular Diseases*  
2013 – present *Diabetes Research and Clinical Practice*  
2013 – present *American Journal of Hypertension*  
2011 – present *Pharmacist's Letter*  
2011 – present *Pharmacotherapy*  
2009 – present *Expert Opinion on Drug Metabolism*  
2008 – present *Annals of Pharmacotherapy*

### Other

2014 – 2016 Managing Editor, *PharmaNote®* Monthly Pharmacy Newsletter, Departments of Pharmacotherapy & Translational Research and Community Health & Family Medicine, Colleges of Pharmacy and Medicine, University of Florida; available at: <http://pharmacy.ufl.edu/pharmanote>  
2013 – 2014 Expert Content Reviewer, *Osteoarthritis* chapter, PSAP-VIII Book 4 *Chronic Illnesses* (ACCP)

- 2012 – 2014      Editor-in-Chief, *Materia Medica*, Monthly Pharmacy Newsletter, Departments of Clinical Pharmacy and Medicine (Division of General Internal Medicine), Schools of Pharmacy and Medicine, University of Colorado
- 2008 – 2011      Assistant Editor, *PharmaNote*® Monthly Pharmacy Newsletter, Departments of Pharmacotherapy & Translational Research and Community Health & Family Medicine, Colleges of Pharmacy and Medicine, University of Florida

## **PROFESSIONAL DEVELOPMENT**

### **Coursework**

*Multi-level Modeling* (PN.140.607.11), Graduate Summer Institute of Epidemiology and Biostatistics, Bloomberg School of Public Health, Johns Hopkins University, Summer 2019

*Intermediate Pharmacoepidemiology* (EPIB 631), McGill University, Summer 2017

*Advanced Pharmacoepidemiology* (EPIB 661), McGill University, Summer 2017

*Applied Cost-Effectiveness Analyses* (PHSC 7611), University of Colorado, Fall 2012

### **Conferences/Seminars/Workshops**

Institute for Academic Leadership, Florida State University System, 2024

New Chair and Director Leadership Development Program, University of Florida, Gainesville, FL, 2023-2024

American Association of Colleges of Pharmacy (AACP) Institute, *Teaching Essentials*, Leesburg, VA, May 20-22, 2013

Colorado Mentoring Training (CO-Mentor) Program, Colorado Clinical and Translational Sciences Institute (CCTSI), University of Colorado, 2012-13

AcademyHealth Health Policy Orientation, Washington, D.C., October 27<sup>th</sup>-29<sup>th</sup>, 2014

IOM Population Health Improvement Roundtable Workshop, *Training in Interdisciplinary Population Health Science: A Vision for the Future*, Washington, D.C., June 1<sup>st</sup>, 2015

IOM Population Health Improvement Roundtable Workshop, *Applying a Health Lens II: The Role and Potential of the Private Sector to Improve Economic Well-Being and Community Outcomes*, Irvine, CA, June 4<sup>th</sup>-5<sup>th</sup>, 2015

IOM Population Health Improvement Roundtable Workshop, *Metrics that Matter for Population Health Action: A Workshop*, Oakland, CA, July 30<sup>th</sup>-31<sup>st</sup>, 2015

IOM Population Health Improvement Roundtable Workshop, *Advancing the Science to Improve Population Health*, Washington D.C., September 30<sup>th</sup>-October 1<sup>st</sup>, 2015

NAM Board on Population Health and Public Health Practice Spring Meeting, Washington D.C., May 24-25, 2016

NAM Board on Health Sciences Policy Spring Meeting, Washington D.C., June 8, 2016

NAM Population Health Improvement Roundtable Workshop, *Community Violence as a Population Health Issue*, Brooklyn, NY, June 16, 2016

NAM Population Health Improvement Roundtable Workshop, *Building Sustainable Financing Structures for Population Health*, Washington D.C., October 19<sup>th</sup>, 2016

NAM Population Health Improvement Roundtable Workshop, *Achieving Rural Health Equity and Well-being: Challenges and Opportunities*, Prattville, AL, June 13<sup>th</sup>, 2017

NHLBI K-to-R01 Investigators Meeting, National Heart Lung and Blood Institute, Bethesda, MD, July 11-12, 2019

UF Leadership Training in Pharmacy (based off UF Academy program), Gainesville, FL, 2020–2021

NHLBI Workshop: The Promise of NHLBI Big Data, National Institutes of Health (virtual due to pandemic), July 20-21, 2021

NHLBI K-to-R01 Investigators Meeting, National Heart Lung and Blood Institute (virtual due to pandemic), July 21-23, 2021

NHLBI K-to-R01 Investigators Meeting, National Heart Lung and Blood Institute (virtual due to pandemic), July 20-22, 2022